kidney

INTERNATIONAL

Volume 34

Editor Emeritus
Roscoe R. Robinson, Nashville

Editor
Thomas E. Andreoli, Little Rock

Associate Editors
Claude Amiel, Paris
James P. Knochel, Dallas

Consulting Editors
J. S. Cameron, London
Ramzi Cotran, Boston
William G. Couser, Seattle
Gerhard Giebisch, New Haven
Nishio Honda, Hamamatsu
Wilhelm Kriz, Heidelberg
François Morel, Paris
Pierre Verroust, Paris

Editorial Board
Vittorio E. Andreucci, Naples
Robert C. Atkins, Melbourne
Knut Aukland, Bergen
Peter Bàlint, Budapest
Rashad Barsoum, Guiza
Jonas Bergstrom, Stockholm
Ori S. Better, Haifa
Roland C. Blantz, San Diego
Jean-Philippe Bonjour, Geneva
Vittorio Bonomini, Bologna
Barry M. Brenner, Boston
Ruth E. Bulger, Washington, D.C.
Anthony R. Clarkson, North Terrace
Jack W. Coburn, Los Angeles
Giuseppe D'Amico, Milan
Vincent W. Dennis, Durham
Evert J. Dorhout Mees, Utrecht
Ratislav Dzúrik, Bratislava
Marilyn G. Farquhar, New Haven
Thomas F. Ferris, Minneapolis
Carmelo Giordano, Naples
Richard J. Glassock, Torrance
Jared J. Grantham, Kansas City
J. P. Grünfeld, Paris
Renée Habib, Paris
Steven C. Hebert, Boston
Lee W. Henderson, Round Lake
Robert H. Heptinstall, Baltimore
Jaime Herrera-Acosta, Mexico City
Klaus Hierholzer, Berlin
Malcolm A. Holliday, San Francisco
Harry Jacobson, Nashville
Rex L. Jamison, Rochester, NY
Colin I. Johnston, Melbourne
D. N. S. Kerr, London
Saulo Klahr, St. Louis
Horst Klinkmann, Rostock
Franklyn G. Knox, Rochester, MN
Franciszek Kokot, Katowice
Rajiv Kumar, Rochester, MN
Kiyoshi Kurokawa, Tokyo
Neil A. Kurtzman, Lubbock
Paul H. Lambert, Geneva
David Z. Levine, Ottawa
Guy Lemieux, Montreal
Francisco Llach, Oklahoma City
Robert G. Luke, Cincinnati
Manuel Martinez-Maldonado, San Juan
Shaul G. Massry, Los Angeles
Alfred F. Michael, Minneapolis
Paul Michielsen, Louvain
William E. Mitch, Atlanta
John F. Moorhead, London
T. J. Neale, Wellington
Karl D. Nolph, Columbia
Tadeusz Orlowski, Warsaw
D. Keith Peters, London
Mordecai M. Popovtzer, Jerusalem
Jaime Borrero Ramirez, Medellin
Jose L. Rodicio, Madrid
Robert W. Schrier, Denver
Jay H. Stein, San Antonio
Liliane Striker, Bethesda
Wadi N. Suki, Houston
Richard L. Tannen, Los Angeles
Gilbert Thiel, Basel
C. Craig Tisher, Gainesville
Karl J. Ullrich, Frankfurt
Heinz Valtin, Hanover
Clark D. West, Cincinnati
Guillermo Whittembury, Caracas
Curtis B. Wilson, La Jolla

Manuscript Editor
Shellie Newell, Little Rock

Editorial Assistant
Joni Till, Little Rock

Springer International

The exclusive copyright for all languages and for all countries, including the right for photomechanical and any other reproductions, also in microform, is transferred to the publisher.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Printed in the United States of America by The William Byrd Press Inc., Richmond, Virginia

© 1988 by International Society of Nephrology

Author Index For Volume 34

Abad C (abst) 289
Abbate M *See* Benigni A et al 164
Achimastos AM *See* Raison JM et al 25:S-122
Ader J-L *See* Durand D et al 25:S-196
Adeva M (abst) 292
Agnusdei D *See* Gennari C et al 25:S-61
Aguado S (abst) 301
Aguilera D, Diab N, Faivre J-M: Influence of sodium dialysate variation on hemodynamic stability ... 25:S-187
Aguilera MT (abst) 298, 299, 299
Alcazar JM (abst) 294
Alcázar JM (abst) 301
Alfino PA, Neugarten J, Schacht RG, Dworkin LD, Baldwin DS: Glomerular size-selective barrier dysfunction in nephrotoxic serum nephritis 151
Alfrey AC *See* Molitoris BA et al 98
Alfrey PS *See* Molitoris BA et al 98
Aljama P (abst) 290, 290, 293, 300
Allon M, Lawson L, Eckman JR, Delaney V, Bourke E: Effects of nonsteroidal antiinflammatory drugs on renal function in sickle cell anemia 500
Almirall J (abst) 289
Alobaidi HMM *See* Topley N et al 404
Alonso S (abst) 291
Alsina J (abst) 298, 301
Alvarez G (abst) 293
Amenôs AM (abst) 298
Amiens C (abst) 564
Amiens CHU (abst) 564
Amor AO *See* Bernard A et al 175
Ancri D *See* Deray G et al 25:S-86
Andersen K-J *See* Haga H-J et al 766
Anderson S: Systemic and glomerular hypertension in progressive renal disease 25:S-119
Andres A (abst) 294, 297
Andres E (abst) 300
Andrés E (abst) 301
Andres G *See* Fukatsu A et al 611
Andres P (abst) 300
Ang KS (abst) 566, 567
Ang KS *See* Simon P et al 25:S-125
Angeli M *See* Moura A-M et al 26:S-8
Angst M (abst) 576
Anouar M *See* Deray G et al 25:S-86
Antón F (abst) 292
Aoyagi T *See* Okubo M et al 467
Aranda P (abst) 293
Ardaillou R (abst) 565
Ardito T *See* Ridderstrale Y et al 655
Arias M (abst) 295
Arisz L (abst) 561, 561
Ariza F (abst) 297
Arnaiz A (abst) 294, 298
Arrázola A (abst) 301
Arriba C (abst) 288
Arriba G (abst) 289
Arroyo F (abst) 290
Asmar RE *See* Raison JM et al 25:S-122
Assmann KJM (abst) 561
Aten J (abst) 556
Atlas SA *See* Laragh JH 25:S-64
Aubert J-F *See* Waeber B et al 26:S-63
Auner I (abst) 563
Aw TY *See* Hagen TM et al 74
Bahlmann J (abst) 573, 573
Bahner U *See* Geiger H et al 25:S-93
Bahner U *See* Geiger H et al 25:S-98
Bahner U *See* Teschner M et al 25:S-156
Balaguer G (abst) 302
Baldwin DS *See* Alfino PA et al 151
Baliga P *See* Domingue GJ et al 761
Ballarin J (abst) 293, 297
Ballina J (abst) 301
Ballon HS *See* Magil AB et al 511
Bandyopadhyay S *See* Soffer RL et al 26:S-69
Bankir L *See* Bouby N et al 4
Baran D *See* Goldman M et al 141
Baranowski RL, Westenfelder C: In vivo renal angiotensin converting enzyme activity decreases in glycerol-induced acute renal failure 321
Barbry P *See* Frelin C et al 26:S-12
Barceló P (abst) 297
Barnes JL, Reznicek MJ, Radnik RA, Venkatachalam MA: Anionization of an antigen promotes glomerular binding and immune complex formation 156
Barrientos A (abst) 289, 296
Barthélémy C (abst) 563
Bartholomay DW *See* Quarles LD et al 840
Bartzke G (abst) 572, 572
Basset JY *See* Deray G et al 25:S-86
Baud L (abst) 565
Baulieu E-E: Molecular mechanism of antisteroid hormones at the receptor level 26:S-2
Baumann PC (abst) 580
Baumelou A (abst) 563
Baumelou A *See* Deray G et al 25:S-86
Beck F-X, Dörge A, Giebisch G, Thurau K: Renal excretion of rubidium and potassium: An electron microprobe and clearance study 455
Beekhuis H (abst) 559, 560
Bell PD *See* Huang W-C et al 631
Bell PE, Hossack KF, Gabow PA, Durr JA, Johnson AM, Schrier RW: Hypertension in autosomal dominant polycystic kidney disease 683
Bellet M *See* Chaignon M et al 25:S-184
Bello I (abst) 297
Benigni A, Chiabrando C, Piccinelli A, Perico N, Gavinelli M, Furci L, Patino O, Abbate M, Bertani T, Remuzzi G: Increased urinary excretion of thromboxane B_2 and 2,3-dinor-TxB_2 in cyclosporin A nephrotoxicity 164
Benzakour M (abst) 564, 564
Bergström J: Catecholamines and control of blood pressure in hemodialysis and hemofiltration 25:S-110
Berland Y *See* Olmer M et al 25:S-129
Bernadet P *See* Durand D et al 25:S-196

Bernard A, Amor AO, Viau C, Lauwerys R: The renal uptake of proteins: A nonselective process in conscious rats 175
Berner M (abst) 571
Bertani T *See* Benigni A et al 164
Berto IM *See* Boero R et al 691
Betz M, Haensch G-M, Rauterberg E-W, Bommer J, Ritz E: Cuprammonium membranes stimulate interleukin 1 release and arachidonic acid metabolism in monocytes in the absence of complement 67
Beutler JJ (abst) 556
Beyer JOM (abst) 560
Bianchi C (abst) 563
Bijvoet OLM *See* Kok DJ et al 346
Binswanger U (abst) 568, 568, 568, 568, 569, 571, 571, 573, 575, 577, 577, 577, 577, 578, 578, 578, 578, 579, 580, 580
Blanchard J (abst) 567
Blazy I *See* Dechaux M et al 25:S-12
Blomen LJMJ *See* Kok DJ et al 346
Blouch K (abst) 562
Blumberg A (abst) 580
Bockenstedt L *See* Petri M et al 832
Böcker R (abst) 570
Boelaert J (abst) 556
Boer P *See* Hené RJ et al 697
Boer WH (abst) 556, 560
Boero R, Guarena C, Deabate MC, Rosati C, Forneris G, Quarello F, Piccoli G: Effects of saline infusion and canrenone on erythrocyte Na^+,K^+ pump activity 25:S-9
Boero R, Guarena C, Berto IM, Deabate MC, Rosati C, Quarello F, Piccoli G: Erythrocyte Na,K pump activity and arterial hypertension in uremic dialyzed patients 691
Boeschoten EW (abst) 561, 561
Bollack C *See* Helwig J-J et al 25:S-45
Bolton WK, Chandra M, Tyson TM, Kirkpatrick PR, Sadovnic MJ, Sturgill BC: Transfer of experimental glomerulonephritis in chickens by mononuclear cells 598
Bommer J *See* Betz M et al 67
Bonati M *See* Viganò G et al 853
Bonjour J-P (abst) 569
Border WA: Distinguishing minimal-change disease from mesangial disorders (Nephrology Forum) 419
Borke JL, Minami J, Verma AK, Penniston JT, Kumar R: Co-localization of erythrocyte Ca^{++}-Mg^{++} ATPase and vitamin D-dependent 28-kDa-calcium binding protein 262
Borum PR *See* Smogorzewski M et al 797
Botella J (abst) 291
Botey A (abst) 289
Bouby N, Trinh-Trang-Tan M-M, Laouari D, Kleinknecht C, Grünfeld J-P, Kriz W, Bankir L: Role of the urinary concentrating process in the renal effects of high protein intake 4
Bouche V (abst) 565
Boudailliez B *See* Idrissi A et al 25:S-138
Bourgoignie JJ *See* Ortiz C et al 248
Bourgoignie JJ *See* Sfakianakis GN et al 25:S-142
Bourke E *See* Allon M et al 500
Brandon DD *See* Chrousos GP et al 26:S-18
Branellec A (abst) 564
Braquet P (abst) 293
Brasseur J (abst) 564, 565
Brenner BM *See* Méndez RE et al 36
Brentjens JR *See* Fukatsu A et al 611
Breuning MH (abst) 557
Brezis M, Shina A, Kidroni G, Epstein FH, Rosen S: Calcium and hypoxic injury in the renal medulla of the perfused rat kidney 186
Briner V (abst) 569
Brinker K *See* Helderman JH et al 376
Brown RS *See* Sugarman A 397
Bruijn JA (abst) 556, 557
Brunner F (abst) 569
Brunner H, Schröder C, van Bennekom C, Lambermon E, Tuerlings J, Menzel D, Olbing H, Monnens L, Wieringa B, Ropers H-H: Localization of the gene for X-linked Alport's syndrome 507
Brunner HR, Waeber B, Nussberger J: Renin secretion responsiveness: Understanding the efficacy of renin-angiotensin inhibition 26:S-80
Brunner HR *See* Waeber B et al 26:S-63
Brunori G *See* Maiorca R et al 518
Buemi M, Corica F, Squadrito F, Ceruso D, Frisina N: Plasma and erythrocyte magnesium concentrations in essential arterial hypertension 25:S-14
Buerkert J *See* Simon EE et al 53
Bueva A (abst) 569
Bukoski RD *See* Hatton DC et al 25:S-16
Buongiorno E *See* Coratelli P et al 25:S-204
Burckhardt P (abst) 572
Burger HR (abst) 573, 579, 580
Bürgisser E (abst) 579
Burke TJ *See* Shanley PF et al 791
Burkhardt F (abst) 570
Burnier M (abst) 579
Bursten S *See* Lovett DH et al 26
Caballero A (abst) 300
Cabello M (abst) 293, 295
Cabezuelo J (abst) 294, 294
Cabrero JG (abst) 288
Cacoub P (abst) 563
Cacoub P *See* Deray G et al 25:S-86
Cada EM *See* Mayer G et al 525
Cahen R (abst) 565
Cajet C (abst) 568, 577
Caldwell PRB *See* Fukatsu A et al 611
Calero F (abst) 297
Callard P (abst) 565, 566
Calvez C (abst) 567
Calvez C *See* Simon P et al 25:S-125
Cam G (abst) 566, 567
Cam G *See* Simon P et al 25:S-125
Camerini C *See* Maiorca R et al 518
Campese VM: Orthostatic hypotension: Idiopathic and uremic 25:S-152
Campese VM *See* Fadda GZ et al 463
Campiche M (abst) 579
Campistol J (abst) 296
Campistol JM (abst) 289, 289, 300
Camussi G *See* Schwertschlag US et al 779
Cancarini GC *See* Maiorca R et al 518
Canga E (abst) 295
Cannata JB (abst) 289, 290, 290
Cantaluppi A *See* Maiorca R et al 518
Capasso G, Giordano DR, Capodicasa G, DeSanto NG: The effect of atrial natriuretic factor on blood pressure and renal function of long-term hypothyroid rats 25:S-104

Capasso G *See* DeSanto NG et al 25:S-115
Capodicasa G *See* Capasso G et al 25:S-104
Capparelli A *See* Suzuki M et al 268
Carayon A (abst) 563
Carayon A *See* Deray G et al 25:S-86
Carreras L (abst) 298
Carretero OA, Scicli AG: Kinins paracrine hormone .. 26:S-52
Carrio J (abst) 291
Casanova P *See* Olmer M et al 25:S-129
Cases A (abst) 289, 292, 295, 295, 296, 296, 300
Casper F (abst) 572, 572
Castelao AM (abst) 301
Castellano M *See* Dal Canton A 273
Castellet R (abst) 293, 297
Castiglione A *See* Sinico RA et al 109
Castilla C (abst) 292
Castillo D (abst) 290, 290, 293, 300
Castillo R (abst) 295, 295
Caverzasio J (abst) 569
Ceruso D *See* Buemi M et al 25:S-14
Cerveró A (abst) 291
Chabardes D (abst) 570
Chaignon M, Bellet M, Lucsko M, Rapoud C, Guédon J: Natriuretic and renal hemodynamic effects of nicardipine in essential hypertension 25:S-184
Chaignon M *See* Guédon J et al 25:S-177
Chaimovitz C *See* Conforty A et al 327
Chakrabarti E *See* Shostak A et al 786
Chan AYM *See* Peterson C et al 825
Chan L *See* Shanley PF et al 791
Chan V *See* Magil AB et al 511
Chandra M *See* Bolton WK et al 598
Charmes JP (abst) 564, 564
Chassande O *See* Frelin C et al 26:S-12
Chatellier G *See* Corvol P et al 25:S-38
Chatellier G *See* Jeunemaitre X et al 26:S-14
Chazot C (abst) 565
Chen N (abst) 565
Chiabrando C *See* Benigni A et al 164
Chisvert J (abst) 300
Choi Y *See* Lee HS et al 537
Chrousos GP, Laue L, Nieman LK, Kawai S, Udelsman RU, Brandon DD, Loriaux DL: Glucocorticoids and glucocorticoid antagonists: Lessons from RU 486 ..... 26:S-18
Cigarran S (abst) 296, 296
Cinotti GA, Pugliese F: Prostaglandins in blood pressure regulation 25:S-57
Claire M (abst) 570
Clapp WL *See* Madsen KM et al 441
Clarici N (abst) 294
Clark M *See* Cody RJ et al 361
Clerici N (abst) 298
Cloup B (abst) 567
Cloup B *See* Simon P et al 25:S-125
Coca A (abst) 298, 299, 299
Codinach P (abst) 291
Cody RJ, Ljungman S, Covit AB, Kubo SH, Sealey JE, Pondolfino K, Clark M, James G, Laragh JH: Regulation of glomerular filtration rate in chronic congestive heart failure patients 361
Coevoet B (abst) 564, 565
Coles GA *See* Topley N et al 404
Collin PH (abst) 565
Colman J *See* Petri M et al 832
Comte L *See* Lucas PA et al 25:S-19
Condorelli M *See* Volpe M et al 25:S-83
Conforty A, Shainkin-Kestenbaum R, Shoshan V, Kol R, Rapoport J, Chaimovitz C: Renal cortical mitochondrial transport of calcium in chronic uremia 327
Coratelli P, Buongiorno E, Giannattasio M, Passavanti G: Antihypertensive efficacy of enalapril maleate on impaired renal function 25:S-204
Corica F *See* Buemi M et al 25:S-14
Coronel F (abst) 289, 296
Corver WE (abst) 557
Corvol MT *See* Corvol P et al 25:S-38
Corvol P, Pinet F, Galen FX, Plouin PF, Chatellier G, Pagny JY, Corvol MT, Ménard J: Seven lessons from seven renin secreting tumors 25:S-38
Corvol P, Ménard J: Renin inhibition: Immunological procedures and renin inhibitor peptides 26:S-73
Corvol P *See* Grünfeld J-P et al 26:S-1
Corvol P *See* Jeunemaitre X et al 26:S-14
Coste T (abst) 566
Cotorruelo JG (abst) 295
Cotran RS: Fifth Annual John Peters Award, American Society of Nephrology. Award recipients: Jacob Churg and Conrad Pirani 121
Cottier C (abst) 577
Cottier C, Matter L, Weidmann P, Shaw S, Gnädinger MP: Renal response to low-dose infusion of atrial natriuretic peptide in normal man 25:S-72
Coudrier E, Kerjaschki D, Louvard D: Cytoskeleton organization and submembranous interactions in intestinal and renal brush borders (Editorial Review) 309
Coulange C *See* Olmer M et al 25:S-129
Covington S *See* Domingue GJ et al 761
Covit AB *See* Cody RJ et al 361
Cuñningham M (abst) 570
Cybulsky AV *See* Quigg RJ et al 43
Da Costa P (abst) 566
Daha MR (abst) 559
Dal Canton A, Castellano M: Theory of urine formation and uroscopic diagnosis in the Medical School of Salerno 273
Dalmeida W, Suki WN: Measurement of GFR with non-radioisotopic radio contrast agents (Technical Note) 725
Dalton RN, Wiseman MJ, Turner C, Viberti G: Measurement of urinary para-aminohippuric acid in glycosuric diabetics (Technical Note) 117
D'Amico G *See* Sinico RA et al 109
Dämmrich J *See* Schafferhans K et al 25:S-101
Daponte R (abst) 293
Daudon M (abst) 566
Davidai GA *See* Quarles LD et al 840
Davies M *See* Topley N et al 404
Dawidson I *See* Helderman JH et al 376
Dawson T (abst) 571
de Alvaro F (abst) 296
de Arriba G (abst) 293
De Bold A *See* Fievet P et al 25:S-89
de Bonis E (abst) 295
De Broe ME (abst) 290
de Castro SS (abst) 295
de Francisco ALM (abst) 295
de Heer E (abst) 556
de Jong PE (abst) 557, 560
de Keijzer MH (abst) 557

de la Sierra A (abst) 298, 299, 299
de Lara AA (abst) 291
De Luca N *See* Volpe M et al 25:S-83
de Merlo MM (abst) 300
de Miguel F (abst) 292
de Nicolas R (abst) 288
de Nicolás R (abst) 288
de Novales EL (abst) 293, 295
de Vinuesa SG (abst) 291
de Vries JDM (abst) 559
de Zeeuw D (abst) 557, 559, 560
Deabate MC *See* Boero R et al 25:S-9
Deabate MC *See* Boero R et al 691
Dechaux M, Kindermans C, Laborde K, Blazy I, Sachs C: Magnesium and plasma renin concentration .. 25:S-12
Degoulet P *See* Jeunemaitre X et al 26:S-14
del Río G (abst) 293
Del Río G (abst) 297
Delaney V *See* Allon M et al 500
Deleide G (abst) 563
DeLuca HF *See* Satomura K et al 712
Demontis R (abst) 564, 565
Dennis VW *See* Schwertschlag US et al 779
Deray C (abst) 563
Deray G, Maistre G, Basset JY, Cacoub P, Carayon A, Anouar M, Baumelou A, Legrand JC, Ancri D, Jacobs C: Plasma levels of atrial natriuretic peptide in chronically dialyzed patients 25:S-86
DeSanto NG, Trevisan M, Capasso G, Giordano DR, Latte M, Krogh V: Blood pressure and hypertension in childhood: Epidemiology, diagnosis, and treatment 25:S-115
DeSanto NG *See* Capasso G et al 25:S-104
Deuber HJ (abst) 570, 570, 570, 576, 576
dez Martin JLF (abst) 289
D'Haese P (abst) 290
Diab N *See* Aguilera D et al 25:S-187
Díaz-López JB (abst) 290
Díaz-Tejeiro R (abst) 301
Díez J (abst) 292, 298, 301
Diez JJ (abst) 296
Diez-Baylon JC (abst) 296
Diggelmann H (abst) 570
Dobrota M *See* Haga H-J et al 766
Doll P *See* Skrabal F et al 25:S-23
Domingue GJ, Laucirica R, Baliga P, Covington S, Robledo JA, Li S-C: Virulence of wild-type *E. coli* uroisolates in experimental pyelonephritis 761
Donadio C (abst) 563
Doñate I (abst) 293
Donker AJM (abst) 560, 560, 561
Dörfler A (abst) 570, 570
Dörge A *See* Beck F-X et al 455
Doucet A: Function and control of Na-K-ATPase in single nephron segments of the mammalian kidney (Editorial Review) 749
Doval M (abst) 292
Drew HH *See* Walser M et al 412
Drüeke T *See* Lucas PA et al 25:S-19
Druet P *See* Goldman M et al 141
Drutarosky MD *See* Verbalis JG 351
Dubach UC (abst) 571, 574, 576
Dunn BR *See* Méndez RE et al 36
Dupont M *See* Mimran A et al 25:S-28
Durand D, Ader J-L, Rey J-P, Tran-Van T, Lloveras J-J, Bernadet P, Suc J-M: Inducing hyperkalemia by converting enzyme inhibitors and heparin ... 25:S-196
Durr JA *See* Bell PE et al 683
Dusso A, Lopez-Hilker S, Rapp N, Slatopolsky E: Extra-renal production of calcitriol in chronic renal failure 368
Dworkin LD *See* Alfino PA et al 151
Eckman JR *See* Allon M et al 500
Egido J (abst) 288, 288, 288, 288
Eisenbach GM (abst) 573, 573
El Esper M (abst) 564
El Esper N *See* Fievet P et al 25:S-89
El Esper N *See* Idrissi A et al 25:S-138
El-Refai M *See* Fadda GZ et al 463
Elema JD (abst) 557
Eloy L *See* Grünfeld J-P 26:S-24
Eloy L *See* Grünfeld J-P 25:S-49
Epstein FH *See* Brezis M et al 186
Eriksson AW (abst) 561
Errasti P (abst) 301
Esbrit P (abst) 292
Escassi A (abst) 290
Escobedo JM (abst) 291
Escolar G (abst) 295, 295
Escuin F (abst) 296
Esparza N (abst) 301
Estreicher J *See* Pascual M et al 529
Fadda GZ, Massry SG, El-Refai M, Campese VM: Alpha$_1$ adrenergic receptors in mesenteric arteries of rats with chronic renal failure 463
Fairley KF *See* Packham DK et al 704
Faivre J-M *See* Aguilera D et al 25:S-187
Farinotti R (abst) 563
Fauchet R (abst) 567
Fauchet R *See* Simon P et al 25:S-125
Fauth C (abst) 570
Favre H (abst) 570, 571, 573
Favre H *See* Fievet P et al 25:S-89
Fdez-Menéndez MJ (abst) 290
Fdez-Soto I (abst) 290
Feller P *See* Maiorca R et al 518
Fernandez JA *See* Ortiz C et al 248
Ferrari G *See* Zuccalà A et al 25:S-190
Ferrier C (abst) 576, 577, 579
Fessi H (abst) 563
Fierro C (abst) 288
Fievet P, Gregoire I, Fournier A, Roth D, Siegenthaler G, El Esper N, Favre H, De Bold A: Ouabain-like natriuretic factor and atrial natriuretic factor in pregnancy 25:S-89
Fievet P *See* Idrissi A et al 25:S-138
Fischer JA *See* Gennari C et al 25:S-61
Fitz G *See* Petri M et al 832
Fleuren GJ (abst) 557, 559
Flores LD (abst) 301
Flückiger J-P *See* Waeber B et al 26:S-63
Fogo A *See* Ichikawa I et al 638
Fonseca D (abst) 293
Fornasieri A *See* Sinico RA et al 109
Forneris G *See* Boero R et al 25:S-9
Fournier A (abst) 564, 565, 565
Fournier A *See* Fievet P et al 25:S-89
Fournier A *See* Idrissi A et al 25:S-138
Franco A (abst) 291, 291, 300
Franco P (abst) 291

François B (abst) 565
Fraser R *See* Tree M et al 25:S-33
Frei D (abst) 571, 579, 580
Frelin C, Barbry P, Chassande O, Vigne P, Lazdunski M: The structure of the amiloride sensitive apical Na^+ channel from pig kidney 26:S-12
Frenken LAM (abst) 558
Friedli B (abst) 571
Fries JWU, Mendrick DL, Rennke HG: Determinants of immune complex-mediated glomerulonephritis 333
Frigon RP *See* Leypoldt JK et al 254
Frisina N *See* Buemi M et al 25:S-14
Frutos MA (abst) 293, 295
Fukatsu A, Yuzawa Y, Niesen N, Matsuo S, Caldwell PRB, Brentjens JR, Andres G: Local formation of immune deposits in rabbit renal proximal tubules 611
Furci L *See* Benigni A et al 164
Gabow PA *See* Bell PE et al 683
Gadela-Parente T (abst) 564
Gagliardi E (abst) 293
Gago E (abst) 301
Gaillard CA (abst) 556, 558
Galen FX *See* Corvol P et al 25:S-38
Gallasch G *See* Hasslacher C et al 25:S-133
Gandhi R (abst) 571, 574
Gantenbein H (abst) 572
Garay RP (abst) 298
Garcés L (abst) 291
Garcia J (abst) 294, 294
Garg LC, Narang N: Effects of aldosterone on NEM-sensitive ATPase in rabbit nephron segments 13
Gaspari F *See* Viganò G et al 853
Gasthuisberg UZ (abst) 562
Gatell JM (abst) 296
Gavinelli M *See* Benigni A et al 164
Gavras H *See* Gavras I 26:S-60
Gavras I, Gavras H: Anti-hormones and blood pressure: Bradykinin antagonists in blood pressure regulation 26:S-60
Gehrig JJ Jr., Ross J, Jamison RL: Effect of long-term, alternate day feeding on renal function in aging conscious rats 620
Geiger H, Bahner U, Palkovits M, Seewaldt B, Heidland A: Is the effect of calcium diet or parathyroidectomy on the development of hypertension in spontaneously hypertensive rats mediated by atrial natriuretic peptide? 25:S-93
Geiger H, Bahner U, Palkovits M, Mezey É, Heidland A: Mechanism of action of atrial natriuretic peptides does not involve adenylate cyclase system of different rat brain areas 25:S-98
Gemsa D *See* Lovett DH et al 26
Genetet B (abst) 567
Genetet B *See* Simon P et al 25:S-125
Gennari C, Nami R, Agnusdei D, Fischer JA: Acute metabolic and cardiovascular effects of human and salmon calcitonin in gene-derived products . 25:S-61
Getino M (abst) 301, 302
Ghezzi PM (abst) 291
Giannattasio M *See* Coratelli P et al 25:S-204
Giebisch G *See* Beck F-X et al 455
Giebisch G *See* Ridderstrale Y et al 655
Gil-Vernet S (abst) 301
Gilchrist SM *See* Schnellmann RG et al 229
Gilli Y (abst) 571, 578
Gimenez M (abst) 294
Giordano DR *See* Capasso G et al 25:S-104
Giordano DR *See* DeSanto NG et al 25:S-115
Girardin E (abst) 571
Glennie J *See* Helderman JH et al 376
Glez-Porqué P (abst) 295
Gmür J (abst) 573
Gnädinger MP (abst) 579
Gnädinger MP *See* Cottier C et al 25:S-72
Goldfarb S: Dietary factors in the pathogenesis and prophylaxis of calcium nephrolithiasis (Nephrology Forum) 544
Goldman M, Baran D, Druet P: Polyclonal activation and experimental nephropathies (Editorial Review) 141
Goldschmeding R (abst) 558
Gómez E (abst) 301
Gomez J (abst) 293
Gonzalez FM (abst) 290
Gonzalez M (abst) 295
González-Cabrero J (abst) 288
Gonzalez-Molina M (abst) 293, 295
Gonzalez-Posada JM (abst) 302
Gonzalo A (abst) 298
Gouault-Heilmann M (abst) 564
Gougoux A *See* Rengel-Aranda M et al 645
Gouyon J-B (abst) 580
Graf H *See* Mayer G et al 525
Grande JA (abst) 301
Gratwohl A (abst) 572
Gregoire I *See* Fievet P et al 25:S-89
Grigoras O (abst) 571
Griñó JM (abst) 301
Griño MC (abst) 296
Groshong T *See* Mactier RA et al 82
Gruber G *See* Skrabal F et al 25:S-23
Grünfeld J-P, Corvol P, Jard S: Introduction 26:S-1
Grünfeld J-P, Eloy L: Glucocorticoid antagonists as probes to study the vascular effects of glucocorticoids 26:S-24
Grünfeld J-P, Eloy L: Role of glucocorticoids in blood pressure regulation 25:S-49
Grünfeld J-P *See* Bouby N et al 4
Guarena C *See* Boero R et al 25:S-9
Guarena C *See* Boero R et al 691
Guédon J, Chaignon M, Lucsko M: Diuretics as antihypertensive drugs 25:S-177
Guédon J *See* Chaignon M et al 25:S-184
Guerola M (abst) 289
Guerrero R (abst) 290, 290
Guidi E, Hollenberg NK: Renovascular responses to angiotensin II in SHR. Effect of prostaglandin synthesis blockade 25:S-149
Guignard J-P (abst) 569, 571, 580
Gutierrez-Millet V (abst) 288, 297
Hackeng WHL (abst) 560
Haddy FJ: Ionic control of vascular smooth muscle cells 25:S-2
Haensch G-M *See* Betz M et al 67
Haga H-J, Andersen K-J, Iversen BM, Ofstad J, Dobrota M, Matre R: Effect of fasting on lysosomes in kidney cortex of glomerulonephritic rats 766
Hagen TM, Aw TY, Jones DP: Glutathione uptake and protection against oxidative injury in isolated kidney cells 74

Hany A (abst) 580
Harris KPG *See* Schreiner GF et al 487
Harvey D *See* Huang W-C et al 631
Hassanein R *See* Richardson WP et al 845
Hasslacher C, Ritz E, Tschöpe W, Gallasch G, Mann JFE: Hypertension in diabetes mellitus 25:S-133
Hatton DC, Muntzel M, McCarron DA, Pressley M, Bukoski RD: Early effects of dietary calcium on blood pressure, plasma volume, and vascular reactivity 25:S-16
Hattori N *See* Saito Y et al 389
Hedlund BE *See* Paller MS et al 474
Heidbreder E, Schafferhans K, Heyd A, Schramm L, Heidland A: Uranyl nitrate-induced acute renal failure in rats: Effect of atrial natriuretic peptide on renal function 25:S-79
Heidbreder E *See* Schafferhans K et al 25:S-101
Heidland A *See* Geiger H et al 25:S-93
Heidland A *See* Geiger H et al 25:S-98
Heidland A *See* Heidbreder E et al 25:S-79
Heidland A *See* Schafferhans K et al 25:S-101
Heidland A *See* Teschner M et al 25:S-156
Heine RJ (abst) 560
Helderman JH, Hernandez J, Sagalowsky A, Dawidson I, Glennie J, Womble D, Toto RD, Brinker K, Hull AR: Confirmation of the utility of fine needle aspiration biopsy of the renal allograft 376
Hellmann D *See* Petri M et al 832
Helwig J-J, Yang MCM, Bollack C, Judes C, Pang PKT: Response of isolated renal microvessel and tubule adenylate cyclases to PTH fragments 25:S-45
Henderson LW *See* Leypoldt JK et al 254
Hendriks JJE (abst) 559
Hené RJ, Koomans HA, Rabelink AJ, Boer P, Mees EJD: Mineralocorticoid activity and the excretion of an oral potassium load in normal man 697
Hens A (abst) 293
Hernandez D (abst) 301, 302, 302
Hernandez E (abst) 289
Hernandez J *See* Helderman JH et al 376
Hernandez L (abst) 293
Hernando L (abst) 288, 288, 288
Herrera J *See* Molina E et al 809
Herrero C (abst) 292
Herrero CL (abst) 300
Herrero J (abst) 295
Herrero JA (abst) 297
Heslan JM (abst) 564
Heule H (abst) 572
Heyd A *See* Heidbreder E et al 25:S-79
Hirszel P *See* Shostak A et al 786
Hodler J (abst) 576
Hoedemaeker PhJ (abst) 557
Hofmann J (abst) 568, 578
Hogendoorn PCW (abst) 557, 559
Hollenberg NK *See* Guidi E 25:S-149
Holloway C *See* Tree M et al 25:S-33
Hopf G (abst) 570
Horstmann E (abst) 575
Hortal L (abst) 289
Hossack KF *See* Bell PE et al 683
Houillier P (abst) 566
Hovinga TKK (abst) 560
Hropot M (abst) 572, 572
Hsu CH *See* Patel S et al 224
Huang W-C, Bell PD, Harvey D, Mitchell KD, Navar LG: Angiotensin influences on tubuloglomerular feedback mechanism in hypertensive rats 631
Huber E (abst) 568, 577
Hugentobler M (abst) 568, 578
Hugentobler MC (abst) 580
Hughes M *See* Tree M et al 25:S-33
Huisman RM (abst) 559
Hull AR *See* Helderman JH et al 376
Hümpfner A (abst) 576
Hunt LP, Short CD, Mallick NP: Prognostic indicators in patients presenting with the nephrotic syndrome 382
Huser B (abst) 572
Ichikawa I, Yoshida Y, Fogo A, Purkerson ML, Klahr S: Effect of heparin on the glomerular structure and function of remnant nephrons 638
Idrissi A, Fournier A, Renaud H, Boudailliez B, El Esper N, Fievet P, Westeel PF, Makdassi R, Remond A: The Captopril challenge test as a screening test for renovascular hypertension 25:S-138
Indart FJ (abst) 292
Indolfi C *See* Volpe M et al 25:S-83
Ingram M *See* Tree M et al 25:S-33
Inoue K *See* Okubo M et al 467
Intrator L (abst) 564
Iranzo RM (abst) 301
Ishida M *See* Satomura K et al 712
Iversen BM *See* Haga H-J et al 766
Jabari NS (abst) 296
Jacobs C (abst) 563
Jacobs C *See* Deray G et al 25:S-86
Jacobs C *See* Olmer M et al 25:S-1
Jacobs JB *See* Quigg RJ et al 43
Jacobson HR: Ischemic renal disease: An overlooked clinical entity? (Nephrology Forum) 729
Jacquet AF (abst) 572
Jaeger P (abst) 572
Jaffe D *See* Ortiz C et al 248
Jaffe DJ *See* Sfakianakis GN et al 25:S-142
Jahn H (abst) 579
Jahn HA *See* Schohn DC et al 25:S-145
James G *See* Cody RJ et al 361
Jamison RL (abst) 562
Jamison RL *See* Gehrig JJ Jr. et al 620
Janssens JP (abst) 573
Jaraba M (abst) 290, 290
Jard S: Mechanisms of action of vasopressin and vasopressin antagonists 26:S-38
Jard S *See* Grünfeld J-P et al 26:S-1
Jeunemaitre X, Kreft-Jais C, Chatellier G, Julien J, Degoulet P, Plouin P-F, Ménard J, Corvol P: Long-term experience of spironolactone in essential hypertension 26:S-14
Jo OD *See* Suzuki M et al 268
Johnson AM *See* Bell PE et al 683
Johnson GC *See* Shanley PF et al 791
Johnson WJ *See* McCarthy JT et al 804
Jones DP *See* Hagen TM et al 74
Jonker GJ (abst) 559
Jover B *See* Mimran A et al 25:S-28
Judes C *See* Helwig J-J et al 25:S-45
Julien J *See* Jeunemaitre X et al 26:S-14
Junco E (abst) 291
Jungbluth H (abst) 573, 579
Jungers P (abst) 566

Kaczmarczyk G (abst) 574
Kaissling B (abst) 571
Kallenberg CGM (abst) 558
Kamata K *See* Okubo M et al 467
Kanterewicz E (abst) 292
Kanwar YS *See* Makino H et al 195
Kanwar YS *See* Makino H et al 209
Kashgarian M *See* Ridderstrale Y et al 655
Kawaguchi Y *See* Suzuki M et al 268
Kawai S *See* Chrousos GP et al 26:S-18
Keith T (abst) 557
Kelly J (abst) 296
Kenouch S (abst) 563
Kerjaschki D *See* Coudrier E et al 309
Keusch G (abst) 568, 571, 573, 578, 579, 580, 580
Khanna R *See* Mactier RA et al 82
Khauli R *See* Strzelecki T et al 234
Kida H *See* Saito Y et al 389
Kidroni G *See* Brezis M et al 186
Kim MJ *See* Lee HS et al 537
Kincaid-Smith PS *See* Packham DK et al 704
Kindermans C *See* Dechaux M et al 25:S-12
Kirkpatrick PR *See* Bolton WK et al 598
Kiron MAR *See* Soffer RL et al 26:S-69
Kiss D (abst) 573
Kiss K (abst) 573
Klahr S *See* Ichikawa I et al 638
Klahr S *See* Schreiner GF et al 487
Kleinknecht C *See* Bouby N et al 4
Klinger W (abst) 575
Knobel H (abst) 292
Ko KW *See* Lee HS et al 537
Koch KM (abst) 573, 573
Koene RAP (abst) 558, 561
Koeppen B *See* Ridderstrale Y et al 655
Koetsier JC (abst) 560
Koh HI *See* Lee HS et al 537
Köhler H (abst) 575, 579
Kohlhaas R (abst) 570, 570
Kok DJ, Papapoulos SE, Blomen LJMJ, Bijvoet OLM: Modulation of calcium oxalate monohydrate crystallization kinetics in vitro 346
Kol R *See* Conforty A et al 327
Kollmar S *See* Rambausek M et al 25:S-201
Könn B (abst) 575
Koomans HA (abst) 556, 556, 558, 560
Koomans HA *See* Hené RJ et al 697
Koomen GCM (abst) 561, 561
Kootte AMM (abst) 559
Koshino Y *See* Saito Y et al 389
Kotanko P *See* Skrabal F et al 25:S-23
Kraehenbuhl J-P (abst) 570
Krämer BK, Ress KM, Ulshöfer TM, Risler T: Hemodynamic and hormonal effects of low or high sodium hemodialysis 25:S-192
Krediet RT (abst) 561, 561
Kreft-Jais C *See* Jeunemaitre X et al 26:S-14
Kriz W *See* Bouby N et al 4
Krogh V *See* DeSanto NG et al 25:S-115
Kubista H (abst) 568, 577
Kubo SH *See* Cody RJ et al 361
Kumar R *See* Borke JL et al 262
Kumar S *See* Strzelecki T et al 234
Kurtz SB *See* McCarthy JT et al 804
L-Revuelta K (abst) 296, 296
Laborde K *See* Dechaux M et al 25:S-12
Lacour B (abst) 566
Lacour B *See* Lucas PA et al 25:S-19
LaFrance ND *See* Walser M et al 412
Lagrue G (abst) 564
Lamas J (abst) 289
Lamas S (abst) 289, 293
Lambermon E *See* Brunner H et al 507
Lamiere N *See* Vanholder R et al 25:S-181
Landmann J (abst) 569
Lang P (abst) 564, 564
Laouari D *See* Bouby N et al 4
Laragh JH, Atlas SA: Atrial natriuretic hormone: A regulator of blood pressure and volume homeostasis 25:S-64
Laragh JH, Resnick LM: Recognizing and treating two types of long-term vasoconstriction in hypertension 25:S-162
Laragh JH *See* Cody RJ et al 361
Largiadèr F (abst) 571, 579
Latte M *See* DeSanto NG et al 25:S-115
Lattmann J (abst) 568, 575, 578, 578
Laucirica R *See* Domingue GJ et al 761
Laue L *See* Chrousos GP et al 26:S-18
Laurent J (abst) 564
Laurent MC (abst) 567
Lauwerys R *See* Bernard A et al 175
Lawson L *See* Allon M et al 500
Lazdunski M *See* Frelin C et al 26:S-12
Le Fiblec B *See* Simon P et al 25:S-125
Le Hir M (abst) 571, 574
Leckie BJ *See* Tree M et al 25:S-33
Lee HS, Choi Y, Yu SH, Koh HI, Kim MJ, Ko KW: A renal biopsy study of hepatitis B virus-associated nephropathy in Korea 537
Leenaerts P *See* Waer M et al 678
Lefiblec B (abst) 567
Leflon P (abst) 565
Legrand JC *See* Deray G et al 25:S-86
Lelongt B *See* Makino H et al 195
Lelongt B *See* Makino H et al 209
Lens XM (abst) 291, 296
Lensen LM (abst) 559
Leroux-Robert C (abst) 564, 564
Levent M (abst) 564
Lever AF *See* Tree M et al 25:S-33
Lévy M (abst) 566
Leypoldt JK, Pust AH, Frigon RP, Henderson LW: Dialysate volume measurements required for determining peritoneal solute transport 254
Li S-C *See* Domingue GJ et al 761
Liaño F (abst) 294
Liard J-F: Vasopressin antagonists and their use in animal studies 26:S-43
Linares M (abst) 291
Linas SL, Marzec-Calvert R, Ullian ME, O'Brien RF: Mechanism of the antihypertensive effect of K depletion in the spontaneously hypertensive rat 18
Lirenman DS *See* Magil AB et al 511
Ljungman S *See* Cody RJ et al 361
Llopis A (abst) 300
Lloveras J-J *See* Durand D et al 25:S-196
Lloyd D *See* Topley N et al 404
Lobaugh B *See* Quarles LD et al 840
Locatelli M *See* Viganò G et al 853
Loizeau E (abst) 570
London GM *See* Raison JM et al 25:S-122

López-Farré A (abst) 293
Lopez-Hilker S *See* Dusso A et al 368
Lopez-Novoa JM (abst) 292
López-Novoa JM (abst) 293
Lopez-Novoa JM *See* Rengel-Aranda M et al 645
Lopez-Pedret J (abst) 289, 295, 295, 296, 296
López-Pedret J (abst) 300
Lorenzo V (abst) 301, 302, 302
Loriaux DL *See* Chrousos GP et al 26:S-18
Lorusso P (abst) 563
Losada M (abst) 301, 302, 302
Louvard D *See* Coudrier E et al 309
Lovett DH, Martin M, Bursten S, Szamel M, Gemsa D, Resch K: Interleukin 1 and the glomerular mesangium. III. Il-1-dependent stimulation of mesangial cell protein kinase activity 26
Lowance DC: Withdrawal from dialysis: An ethical perspective (Nephrology Forum) 124
Lozano L (abst) 288
Lucas PA, Lacour B, Comte L, McCarron DA, Drüeke T: Abnormal parameters of acid-base balance in genetic hypertension 25:S-19
Lucsko M *See* Chaignon M et al 25:S-184
Lucsko M *See* Guédon J et al 25:S-177
Luik AJ (abst) 560
Lumbreras C (abst) 297
Lunghi F (abst) 563
Luño J (abst) 291, 291, 300
Maceira B (abst) 301, 302, 302
Macon K *See* Pascual M et al 529
Mactier RA, Khanna R, Moore H, Russ J, Nolph KD, Groshong T: Kinetics of peritoneal dialysis in children: Role of lymphatics 82
Madsen B *See* Peterson C et al 825
Madsen KM, Clapp WL, Verlander JW: Structure and function of the inner medullary collecting duct (Editorial Review) 441
Maduell F (abst) 301
Magil AB, Puterman ML, Ballon HS, Chan V, Lirenman DS, Rae A, Sutton RAL: Prognostic factors in diffuse proliferative lupus glomerulonephritis 511
Maher JF *See* Shostak A et al 786
Mahmoud MD (abst) 565
Maiorca R, Vonesh E, Cancarini GC, Cantaluppi A, Manili L, Brunori G, Camerini C, Feller P, Strada A: A six-year comparison of patient and technique survivals in CAPD and HD 518
Maistre G (abst) 563
Maistre G *See* Deray G et al 25:S-86
Makdassi R (abst) 564
Makdassi R *See* Idrissi A et al 25:S-138
Makino H, Lelongt B, Kanwar YS: Nephritogenicity of proteoglycans. II. A model of immune complex nephritis 195
Makino H, Lelongt B, Kanwar YS: Nephritogenicity of proteoglycans. III. Mechanism of immune deposit formation 209
Malé P-J (abst) 570
Mall G *See* Rambausek M et al 25:S-201
Mallafre JM (abst) 291
Mallick NP *See* Hunt LP et al 382
Mallol J (abst) 290, 300
Malo M (abst) 294
Mampaso F (abst) 288
Mandel LJ *See* Schnellmann RG et al 229
Manili L *See* Maiorca R et al 518
Mann JFE *See* Hasslacher C et al 25:S-133
Manning M *See* Sawyer WH 26:S-34
Manzano F (abst) 292
Marcén R (abst) 294, 294, 297
Markert M (abst) 575
Martin D *See* Simon EE et al 53
Martín FG (abst) 294
Martin G (abst) 295
Martin JLF (abst) 290
Martin M *See* Lovett DH et al 26
Martin-Malo A (abst) 290, 290, 293, 300
Martinez JA (abst) 296
Martul EV (abst) 292
Marx M (abst) 574, 575, 579
Marzec-Calvert R *See* Linas SL et al 18
Masaki Y *See* Okubo M et al 467
Mason DY (abst) 558
Massry SG *See* Fadda GZ et al 463
Massry SG *See* Olmer M et al 25:S-1
Massry SG *See* Perna AF et al 774
Massry SG *See* Smogorzewski M et al 797
Matesanz R (abst) 294, 295, 297
Mathews DC *See* Packham DK et al 704
Matre R *See* Haga H-J et al 766
Matsuo S *See* Fukatsu A et al 611
Matter L *See* Cottier C et al 25:S-72
Mayer G, Thum J, Cada EM, Stummvoll HK, Graf H: Working capacity is increased following recombinant human erythropoietin treatment 525
Mayet W (abst) 579
Mazzoleni A *See* Remuzzi A et al 481
McCarron D *See* Olmer M et al 25:S-1
McCarron DA *See* Hatton DC et al 25:S-16
McCarron DA *See* Lucas PA et al 25:S-19
McCarthy JT, Milliner DS, Schmidt DF, Schniepp BJ, Kurtz SB, Johnson WJ: Deferoxamine and coated charcoal hemoperfusion to remove aluminum in dialysis patients 804
Medel AS (abst) 289
Medow MS *See* Spencer PD et al 671
Mees EJD (abst) 556, 556, 558, 560
Mees EJD *See* Hené RJ et al 697
Meister B *See* Skrabal F et al 25:S-23
Mele AF *See* Volpe M et al 25:S-83
Ménard J *See* Corvol P et al 25:S-38
Ménard J *See* Corvol P et al 26:S-73
Ménard J *See* Jeunemaitre X et al 26:S-14
Méndez RE, Dunn BR, Troy JL, Brenner BM: Atrial natriuretic peptide and furosemide effects on hydraulic pressure in the renal papilla 36
Mendrick DL *See* Fries JWU et al 333
Meneses R *See* Ortiz C et al 248
Menon M *See* Strzelecki T et al 234
Menzel D (abst) 561
Menzel D *See* Brunner H et al 507
Méry JPh (abst) 563, 567
Messier G (abst) 565, 566
Mestre M (abst) 301
Mestres CA (abst) 289
Meuwissen SGM (abst) 561
Meyer TW *See* Miller PL 220
Meyer zum Büschenfelde KH (abst) 575
Meyer-Lehnert H, Schrier RW: Cyclosporine A enhances vasopressin-induced Ca^{2+} mobilization and contraction in mesangial cells 89
Meyrier A (abst) 565, 566

Mezey É *See* Geiger H et al. 25:S-98
Miach PJ (abst) 294
Michielsen P (abst) 558, 562
Michielsen P *See* Waer M et al 678
Miguel JL (abst) 296
Miguelez C (abst) 296
Mihatsch MJ (abst) 572
Miller H (abst) 575
Miller NL *See* Molitoris BA et al. 98
Miller PL, Meyer TW: Plasma protein concentration and colloid osmotic pressure in nephrotic rats 220
Milliner DS *See* McCarthy JT et al 804
Mimran A, Jover B, Dupont M: Enalapril-induced disturbance in the renal adaptation to sodium restriction in the rat 25:S-28
Minami J *See* Borke JL et al 262
Miranda B (abst) 301
Mitchell KD *See* Huang W-C et al. 631
Miyahara T *See* Suzuki M et al. 268
Moesch C (abst) 564
Molina E, Herrera J, Rodríguez-Iturbe B: The renal functional reserve in healthy and renal disease in school age children 809
Molitoris BA, Alfrey AC, Alfrey PS, Miller NL: Rapid removal of DFO-chelated aluminum during hemodialysis using polysulfone dialyzers 98
Moll R (abst) 291
Molzahn M (abst) 569
Monnens L *See* Brunner H et al 507
Monnens LAH (abst) 559, 561
Monteagudo J (abst) 295, 295
Montés C (abst) 563
Montoliu J (abst) 296, 298, 299, 299, 300
Moore H *See* Mactier RA et al. 82
Morales JM (abst) 294, 297
Morales Z (abst) 302
Moreno CS (abst) 291
Moreno E (abst) 293
Moreno RF (abst) 294
Morinière P (abst) 564
Morris PJ (abst) 294
Morton JJ *See* Tree M et al 25:S-33
Moses LC *See* Spencer PD et al 671
Mosimann R (abst) 579
Möslein J *See* Teschner M et al 25:S-156
Moullier P (abst) 562
Moura A-M, Angeli M, Worcel M: Extrarenal effects of aldosterone and antimineralocorticoid compounds 26:S-8
Mühlbauer HG (abst) 570
Mulet J (abst) 289
Muñoz J (abst) 296, 296
Muñoz R (abst) 293
Muñoz-Gómez J (abst) 300
Muntzel M *See* Hatton DC et al 25:S-16
Myers BD *See* Peterson C et al. 825
Nami R *See* Gennari C et al 25:S-61
Narang N *See* Garg LC. 13
Naranjo P (abst) 289
Navar LG *See* Huang W-C et al. 631
Neugarten J *See* Alfino PA et al. 151
Neveceral P (abst) 575
Nieman LK *See* Chrousos GP et al 26:S-18
Niesen N *See* Fukatsu A et al 611
Nieter B (abst) 575
Nieto LH (abst) 302
Ninot S (abst) 289
Noel C (abst) 565
Nolph KD *See* Mactier RA et al. 82
Noordally R *See* Olmer M et al. 25:S-129
Nouewen EJ (abst) 290
Novoa JML (abst) 289, 293
Nussberger J *See* Brunner HR et al. 26:S-80
Nussberger J *See* Waeber B et al 26:S-63
O'Brien RF *See* Linas SL et al. 18
Ofstad J *See* Haga H-J et al 766
Oguma S: A histometrical study on the development of three glomerulopathies 102
Ogura Y *See* Suzuki M et al. 268
Ohrisch G (abst) 570, 570
Okubo M, Inoue K, Umetani N, Sato N, Kamata K, Masaki Y, Uchiyama T, Yan X-J, Aoyagi T, Shirai T: Lupus nephropathy in New Zealand F1 hybrid mice treated by (-)15-deoxyspergualin 467
Olbing H *See* Brunner H et al. 507
Oliet A (abst) 297, 301
Oliva JA (abst) 291
Oliver A (abst) 297
Oliver J (abst) 292
Olivera A (abst) 289, 293
Oliveros R (abst) 297
Olmer M, Jacobs C, Massry SG, McCarron D: Introduction. 25:S-1
Olmer M, Noordally R, Berland Y, Casanova P, Coulange C, Rampal M: Hypertension in renal transplantation 25:S-129
Ordinas A (abst) 295
Orofino L (abst) 295, 297
Orte L (abst) 294
Ortíz A (abst) 288
Ortiz C, Meneses R, Jaffe D, Fernandez JA, Perez G, Bourgoignie JJ: Outcome of patients with human immunodeficiency virus on maintenance hemodialysis 248
Ortuño J (abst) 294, 295, 297, 298
P-Diaz V (abst) 296
Packham DK, Mathews DC, Fairley KF, Whitworth JA, Kincaid-Smith PS: Morphometric analysis of pre-eclampsia in women biopsied in pregnancy and post-partum 704
Pagny JY *See* Corvol P et al. 25:S-38
Palkovits M *See* Geiger H et al. 25:S-93
Palkovits M *See* Geiger H et al. 25:S-98
Pallardo LM (abst) 294, 294
Paller MS, Hedlund BE: Role of iron in postischemic renal injury in the rat 474
Pals G (abst) 561
Pang PKT *See* Helwig J-J et al 25:S-45
Papapoulos SE *See* Kok DJ et al. 346
Pardo-Mindán F (abst) 298
Pascual M, Steiger G, Estreicher J, Macon K, Volanakis JE, Schifferli JA: Metabolism of complement factor D in renal failure. 529
Pascual R (abst) 291
Passavanti G *See* Coratelli P et al. 25:S-204
Patel S, Simpson RU, Hsu CH: Calcitriol synthesis is decreased in spontaneously hypertensive rats 224
Patino O *See* Benigni A et al 164
Paul LC (abst) 559
Paunier L (abst) 571
Pearson PL (abst) 557
Pech MA (abst) 564, 564

Pedrini LA, Zereik S, Rasmy S: Causes, kinetics and clinical implications of post-hemodialysis urea rebound 817
Pelaez E (abst) 297
Penniston JT *See* Borke JL et al 262
Pérez A (abst) 291
Perez G *See* Ortiz C et al 248
Perez J (abst) 565
Pérez JL (abst) 300
Perez R (abst) 291, 293, 300, 300
Perez-Fontan M (abst) 292
Perez-Garcia R (abst) 291
Perico N *See* Benigni A et al 164
Perlman A *See* Peterson C et al 825
Perna AF, Smogorzewski M, Massry SG: Verapamil reverses PTH- or CRF-induced abnormal fatty acids oxidation in muscle 774
Perna AF *See* Smogorzewski M et al 797
Peters J (abst) 568, 578
Peterson C, Madsen B, Perlman A, Chan AYM, Myers BD: Atrial natriuretic peptide and the renal response to hypervolemia in nephrotic humans 825
Petri M, Bockenstedt L, Colman J, Whiting-O'Keefe Q, Fitz G, Sebastian A, Hellmann D: Serial assessment of glomerular filtration rate in lupus nephropathy 832
Peyronnet P (abst) 564
Piccinelli A *See* Benigni A et al 164
Piccoli G *See* Boero R et al 25:S-9
Piccoli G *See* Boero R et al 691
Piers DA (abst) 559, 560
Pilorgé M (abst) 567
Pilorge M *See* Simon P et al 25:S-125
Pinet F *See* Corvol P et al 25:S-38
Pinnick RP *See* Richardson WP et al 845
Plouin P-F *See* Jeunemaitre X et al 26:S-14
Plouin PF *See* Corvol P et al 25:S-38
Pondolfino K *See* Cody RJ et al 361
Portmann L (abst) 572
Posada JG (abst) 301
Posada JMG (abst) 302
Pothoff G (abst) 575
Pozo C (abst) 289
Praga M (abst) 297
Precht K (abst) 575
Pressley M *See* Hatton DC et al 25:S-16
Prieto C (abst) 294
Prieto J (abst) 292
Probst W (abst) 568, 575, 578, 578
Pronk JC (abst) 561
Provoost AP (abst) 557
Pugliese F *See* Cinotti GA 25:S-57
Puntorieri S *See* Remuzzi A et al 481
Purkerson ML *See* Ichikawa I et al 638
Purkerson ML *See* Schreiner GF et al 487
Purroy A (abst) 292, 301
Pusineri F *See* Viganò G et al 853
Pust AH *See* Leypoldt JK et al 254
Puterman ML *See* Magil AB et al 511
Puyol DR (abst) 289
Quarello F *See* Boero R et al 25:S-9
Quarello F *See* Boero R et al 691
Quarles LD, Davidai GA, Schwab SJ, Bartholomay DW, Lobaugh B: Oral calcitriol and calcium: Effient therapy for uremic hyperparathyroidism 840
Quereda C (abst) 297
Quigg RJ, Cybulsky AV, Jacobs JB, Salant DJ: Anti-Fx1A produces complement-dependent cytotoxicity of glomerular epithelial cells 43
Quintela MJ (abst) 297
Rabelink AJ (abst) 556, 560
Rabelink AJ *See* Hené RJ et al 697
Rabelink TJ (abst) 558
Radnik RA *See* Barnes JL et al 156
Rae A *See* Magil AB et al 511
Rainfray M (abst) 565, 566
Raison JM, Safar ME, Asmar RE, Achimastos AM, London GM: Sex dependence of body fat distribution and fluid volumes in hypertension 25:S-122
Rama H (abst) 298
Rambausek M, Mall G, Kollmar S, Ritz E: Effect of converting enzyme inhibitors on cardiac changes in experimental uremia 25:S-201
Ramée MP (abst) 566
Ramirez F (abst) 288
Ramos B (abst) 295
Ramos P (abst) 296
Rampal M *See* Olmer M et al 25:S-129
Rapoport J *See* Conforty A et al 327
Rapoud C *See* Chaignon M et al 25:S-184
Rapp N *See* Dusso A et al 368
Rasmy S *See* Pedrini LA et al 817
Rauterberg E-W *See* Betz M et al 67
Rebstöck W (abst) 576
Reeders ST (abst) 557
Reinhardt HW (abst) 574
Reissi D (abst) 565
Remond A *See* Idrissi A et al 25:S-138
Remuzzi A, Puntorieri S, Mazzoleni A, Remuzzi G: Sex related differences in glomerular ultrafiltration and proteinuria in Munich-Wistar rats 481
Remuzzi G *See* Benigni A et al 164
Remuzzi G *See* Remuzzi A et al 481
Remuzzi G *See* Viganò G et al 853
Renaud H (abst) 564, 565
Renaud H *See* Idrissi A et al 25:S-138
Rengel M (abst) 292
Rengel-Aranda M, Gougoux A, Vinay P, Lopez-Novoa JM: Effect of valproate on renal metabolism in the intact dog 645
Rennke HG *See* Fries JWU et al 333
Requena MJ (abst) 290
Resch K *See* Lovett DH et al 26
Resnick LM *See* Laragh JH 25:S-162
Ress KM *See* Krämer BK et al 25:S-192
Reutter FW (abst) 572
Reveillaud RJ (abst) 566
Revert L (abst) 289, 289, 292, 295, 295, 296, 296, 300
Rey J-P *See* Durand D et al 25:S-196
Reznicek MJ *See* Barnes JL et al 156
Richardson WP, Hassanein R, Pinnick RP, Savin VJ: Ultrafiltration coefficients of glomeruli from human biopsies 845
Rico H (abst) 289
Ridderstrale Y, Kashgarian M, Koeppen B, Giebisch G, Stetson D, Ardito T, Stanton B: Morphological heterogeneity of the rabbit collecting duct 655
Rincé M (abst) 564, 564
Ringoir S (abst) 291
Ringoir S *See* Vanholder R et al 25:S-181
Risler T *See* Krämer BK et al 25:S-192
Ritz E *See* Betz M et al 67

Ritz E *See* Hasslacher C et al 25:S-133
Ritz E *See* Rambausek M et al 25:S-201
Rivera MP *See* Volpe M et al 25:S-83
Robben JCM (abst) 561
Robinson RR: A birthday for the Forum 1
Robledo JA *See* Domingue GJ et al 761
Robles A (abst) 288
Robles R (abst) 291
Robles RG (abst) 301
Roch-Ramel F (abst) 570
Rochera A (abst) 294, 294
Rodero FG (abst) 297
Rodicio JL (abst) 294, 301
Rodrigo PP (abst) 293
Rodriguez JC (abst) 302
Rodríguez MJ (abst) 288
Rodríguez-Iturbe B *See* Molina E et al 809
Rodríguez-Puyol D (abst) 293
Roels L *See* Waer M et al 678
Ronco P (abst) 562
Ropers H-H *See* Brunner H et al 507
Roques BP: Physiological role of endogenous peptide effectors studied with peptidase inhibitors 26:S-27
Rosati C *See* Boero R et al 25:S-9
Rosati C *See* Boero R et al 691
Röseler E (abst) 575
Rosen S *See* Brezis M et al 186
Rosenberg E *See* Soffer RL et al 26:S-69
Rosner B (abst) 576
Ross J *See* Gehrig JJ Jr. et al 620
Rossier B (abst) 570
Rostan A (abst) 573
Rostoker G (abst) 564, 564
Roth D *See* Fievet P et al 25:S-89
Roth KS *See* Spencer PD et al 671
Rouge JC (abst) 571
Rouse D *See* Suki WN 25:S-160
Ruilope LM (abst) 294, 301
Ruiz-Gonzalez MC (abst) 296
Russ J *See* Mactier RA et al 82
Sabadini E *See* Sinico RA et al 109
Sabaté I (abst) 301
Sabater F (abst) 296
Sabater R (abst) 301
Sachs C *See* Dechaux M et al 25:S-12
Sadovnic MJ *See* Bolton WK et al 598
Safar ME *See* Raison JM et al 25:S-122
Sagalowsky A *See* Helderman JH et al 376
Saito Y, Kida H, Takeda S, Yoshimura M, Yokoyama H, Koshino Y, Hattori N: Mesangiolysis in diabetic glomeruli: Its role in the formation of nodular lesions 389
Salant DJ *See* Quigg RJ et al 43
Salvadori P (abst) 563
Salvatierra A (abst) 290
Sanchez J (abst) 294, 294
Sánchez M (abst) 291, 297
Sanchez P (abst) 294
Sánchez-Casajús A (abst) 298
Sanchis J (abst) 291
Sancho J (abst) 301
Sans D (abst) 297
Santoro A (abst) 291
Santoro A *See* Zuccalà A et al 25:S-190
Sarrias X (abst) 298
Sato N *See* Okubo M et al 467
Satomura K, Seino Y, Yamaoka K, Tanaka Y, Ishida M, Yabuuchi H, Tanaka Y, DeLuca HF: Renal 25-hydroxyvitamin D_3-1-hydroxylase in patients with renal disease 712
Savage COS (abst) 561
Savin VJ *See* Richardson WP et al 845
Sawyer WH, Manning M: The development of potent and specific vasopressin antagonists 26:S-34
Saxenhofer H (abst) 576, 577
Schacht RG *See* Alfino PA et al 151
Schaefer RM *See* Teschner M et al 25:S-156
Schafferhans K, Heidbreder E, Sperber S, Dämmrich J, Heidland A: Atrial natriuretic peptide in gentamicin-induced acute renal failure 25:S-101
Schafferhans K *See* Heidbreder E et al 25:S-79
Schaffner A (abst) 579
Schalekamp MA *See* Zietse R 717
Schalkwijk J (abst) 561
Schifferli JA *See* Pascual M et al 529
Schmidt DF *See* McCarthy JT et al 804
Schmit JL (abst) 564
Schmitt RL *See* Schohn DC et al 25:S-145
Schneider E (abst) 573
Schnellmann RG, Gilchrist SM, Mandel LJ: Intracellular distribution and depletion of glutathione in rabbit renal proximal tubules 229
Schniepp BJ *See* McCarthy JT et al 804
Schohn D (abst) 579
Schohn DC, Jahn HA, Schmitt RL: Predictability of a standardized Captopril^R-test in hypertension in end-stage renal failure 25:S-145
Schramm L *See* Heidbreder E et al 25:S-79
Schreiner GF, Harris KPG, Purkerson ML, Klahr S: Immunological aspects of acute ureteral obstruction: Immune cell infiltrate in the kidney 487
Schrier RW *See* Bell PE et al 683
Schrier RW *See* Meyer-Lehnert H 89
Schrijver G (abst) 558, 561
Schröder C *See* Brunner H et al 507
Schröder CH (abst) 559, 561
Schulz W (abst) 570, 570, 576
Schwab SJ *See* Quarles LD et al 840
Schwertschlag US, Dennis VW, Tucker JA, Camussi G: Nonimmunological alterations of glomerular filtration by s-PAF in the rat kidney 779
Scicli AG *See* Carretero OA 26:S-52
Sealey JE *See* Cody RJ et al 361
Sebastian A *See* Petri M et al 832
Sebert JL (abst) 564
Seewaldt B *See* Geiger H et al 25:S-93
Segaert M (abst) 556
Seifter JL *See* Zeidel ML 60
Seino Y *See* Satomura K et al 712
Selgas R (abst) 296, 296
Serrano M (abst) 289
Servitje E (abst) 297
Seufert R (abst) 572, 572
Sfakianakis GN, Jaffe DJ, Bourgoignie JJ: Captopril scintigraphy in the diagnosis of renovascular hypertension 25:S-142
Shah SV *See* Thakur V et al 494
Shainkin-Kestenbaum R *See* Conforty A et al 327
Shanley PF, Shapiro JI, Chan L, Burke TJ, Johnson GC: Acidosis and hypoxic medullary injury in the isolated perfused rat kidney 791
Shapiro JI *See* Shanley PF et al 791

Shaw S *See* Cottier C et al 25:S-72
Shaw SG (abst) 576, 576, 577
Shina A *See* Brezis M et al 186
Shirai T *See* Okubo M et al 467
Short CD *See* Hunt LP et al 382
Shoshan V *See* Conforty A et al 327
Shostak A, Chakrabarti E, Hirszel P, Maher JF: Effects of histamine and its receptor antagonists on peritoneal permeability 786
Siegenthaler G *See* Fievet P et al 25:S-89
Simon EE, Martin D, Trigg D, Buerkert J: Contribution of the distal tubule to potassium excretion in experimental glomerulonephritis 53
Simon P (abst) 566, 567
Simon P, Fauchet R, Pilorge M, Calvez C, Le Fiblec B, Cam G, Ang KS, Genetet B, Cloup B: Association of HLA DR4 with the risk of recurrence of pregnancy hypertension 25:S-125
Simpson RU *See* Patel S et al 224
Sinico RA, Winearls CG, Sabadini E, Fornasieri A, Castiglione A, D'Amico G: Identification of glomerular immune deposits in cryoglobulinemia glomerulonephritis 109
Sitprija V: Nephropathy in falciparum malaria (Nephrology Forum) 867
Skrabal F, Kotanko P, Meister B, Doll P, Gruber G: Augmented rise of α_2/β_2 adrenoceptor ratio induced by salt and essential hypertension 25:S-23
Slatopolsky E *See* Dusso A et al 368
Sluiter HE (abst) 558
Smogorzewski M, Perna AF, Borum PR, Massry SG: Fatty acid oxidation in the myocardium: Effects of parathryoid hormone and CRF 797
Smogorzewski M *See* Perna AF et al 774
Sobrino X (abst) 292
Soffer RL, Kiron MAR, Rosenberg E, Bandyopadhyay S: Angiotensin receptor: Properties and relevance to the development of antagonists 26:S-69
Solá R (abst) 293
Solé M (abst) 300
Soriano JR (abst) 297
Soriano MA (abst) 300
Speck B (abst) 572
Spencer PD, Medow MS, Moses LC, Roth KS: Effects of succinylacetone on the uptake of sugars and amino acids by brush border vesicles 671
Sperber S *See* Schafferhans K et al 25:S-101
Squadrito F *See* Buemi M et al 25:S-14
Stamatakis G (abst) 563
Stanton B *See* Ridderstrale Y et al 655
Stauffer JC (abst) 579
Steiger G *See* Pascual M et al 529
Stetson D *See* Ridderstrale Y et al 655
Stewart JM *See* Waeber B et al 26:S-63
Strada A *See* Maiorca R et al 518
Strijk SP (abst) 559
Struijk DG (abst) 561, 561
Strzelecki T, Kumar S, Khauli R, Menon M: Impairment by cyclosporine of membrane-mediated functions in kidney mitochondria 234
Stummvoll HK *See* Mayer G et al 525
Sturgill BC *See* Bolton WK et al 598
Stürmer T (abst) 576
Stutz B (abst) 568, 569, 577, 577, 578
Suc J-M *See* Durand D et al 25:S-196
Suda S (abst) 577
Sugarman A, Brown RS: The role of aldosterone in potassium tolerance: Studies in anephric humans 397
Suki WN, Rouse D: Renal tubular actions of antihypertensive agents 25:S-160
Suki WN: Dietary potassium and blood pressure 25:S-175
Suki WN *See* Dalmeida W 725
Sulková S, Válek A: Role of antihypertensive drugs in the therapy of patients on regular dialysis treatment 25:S-198
Suria S (abst) 301, 302
Sutton RAL *See* Magil AB et al 511
Suzuki M, Capparelli A, Jo OD, Kawaguchi Y, Ogura Y, Miyahara T, Yanagawa N: Phosphate transport in the in vitro cultured rabbit proximal convoluted and straight tubules (Technical Note) 268
Szamel M *See* Lovett DH et al 26
Szelke M *See* Tree M et al 25:S-33
Takeda S *See* Saito Y et al 389
Tanaka Y *See* Satomura K et al 712
Tanaka Y *See* Satomura K et al 712
Taylor CJ (abst) 294
ten Kate RW (abst) 561
Tervaert JWC (abst) 558
Teschner M, Bahner U, Schaefer RM, Möslein J, Heidland A: Early functional effects of various antihypertensive drugs in chronically uremic rats 25:S-156
Thakur V, Walker PD, Shah SV: Evidence suggesting a role for hydroxyl radical in puromycin aminonucleoside-induced proteinuria 494
Thibonnier M: Use of vasopressin antagonists in human diseases 26:S-48
Thibonnier M: Vasopressin and blood pressure 25:S-52
Thiel G (abst) 569, 572
Thum J *See* Mayer G et al 525
Thurau K *See* Beck F-X et al 455
Ting A (abst) 294
Topley N, Alobaidi HMM, Davies M, Coles GA, Williams JD, Lloyd D: The effect of dialysate on peritoneal phagocyte oxidative metabolism 404
Torralbo M (abst) 293
Torras A (abst) 289, 296, 300
Torrente J (abst) 296
Torres A (abst) 301, 302, 302
Toto RD *See* Helderman JH et al 376
Tramonti G (abst) 563
Tran-Van T *See* Durand D et al 25:S-196
Tree M, Fraser R, Holloway C, Hughes M, Ingram M, Leckie BJ, Lever AF, Morton JJ, Szelke M: Role of renin as a blood-borne hormone tested by infusion of renin inhibitor (H.77) 25:S-33
Trevisan M *See* DeSanto NG et al 25:S-115
Trigg D *See* Simon EE et al 53
Trimarco B *See* Volpe M et al 25:S-83
Trinh-Trang-Tan M-M *See* Bouby N et al 4
Trolliet P (abst) 565
Trouvin J-H (abst) 563
Troy JL *See* Méndez RE et al 36
Tschöpe W *See* Hasslacher C et al 25:S-133
Tucker JA *See* Schwertschlag US et al 779
Tuerlings J *See* Brunner H et al 507
Turner C *See* Dalton RN et al 117
Tyson TM *See* Bolton WK et al 598
Ubetagoyena M (abst) 297
Uchiyama T *See* Okubo M et al 467
Udelsman RU *See* Chrousos GP et al 26:S-18
Ullian ME *See* Linas SL et al 18

Ulshöfer TM *See* Krämer BK et al 25:S-192
Umetani N *See* Okubo M et al 467
Urbano-Márquez A (abst) 298, 299, 299
V.d. Heijden AJ (abst) 571
v.d. Heuvel L (abst) 561
Valderrabano F (abst) 291, 291, 300
Valdes F (abst) 292
Válek A *See* Sulková S 25:S-198
Vallo A (abst) 297
Vallotton M (abst) 571
Valverde VM (abst) 300
van Bennekom C *See* Brunner H et al 507
van Bockel JH (abst) 559
Van Damme B *See* Waer M et al 678
van de Stolpe A (abst) 562
van der Hem GK (abst) 557, 559, 560
van der Schoot CE (abst) 558
Van Der Schueren E *See* Waer M et al 678
van Dorst EBL (abst) 559
van Es AL (abst) 557
van Es LA (abst) 559
van Hattum J (abst) 556
van Leer EHG (abst) 562
van Ommen GJB (abst) 557
Van Roost G (abst) 556
van Ypersele de Strihou C (abst) 567
Vandeputte M *See* Waer M et al 678
Vanholder R (abst) 291
Vanholder R, Lamiere N, Ringoir S: Therapeutic effect and complication profile of clonidine-beta-blocker combinations 25:S-181
Vanrenterghem Y (abst) 562
Vargas C (abst) 293
Vavrek RJ *See* Waeber B et al 26:S-63
vd Broek LJCM (abst) 557
vd Reijden HJ (abst) 561, 561
Veech RL: The untoward effects of the anions of dialysis fluids (Editorial Review) 587
Veerkamp JH (abst) 561
Vega FF (abst) 301
Velo M (abst) 288
Veninga A (abst) 556
Venkatachalam MA *See* Barnes JL et al 156
Verbalis JG, Drutarosky MD: Adaptation to chronic hypoosmolality in rats 351
Verbanck J (abst) 556
Verberckmoes R (abst) 558
Verlander JW *See* Madsen KM et al 441
Verma AK *See* Borke JL et al 262
Verroust P (abst) 562
Viau C *See* Bernard A et al 175
Viberti G *See* Dalton RN et al 117
Vicario JL (abst) 294, 298
Viganò G, Gaspari F, Locatelli M, Pusineri F, Bonati M, Remuzzi G: Dose-effect and pharmacokinetics of estrogens given to correct bleeding time in uremia 853
Vigne P *See* Frelin C et al 26:S-12
Vila R (abst) 293
Vilardell M (abst) 292
Villar ML (abst) 295
Villaro J (abst) 291
Vinay P *See* Rengel-Aranda M et al 645
Virgos MJ (abst) 290
Vögtli J (abst) 568, 568, 569, 577, 577, 577, 578
Volanakis JE *See* Pascual M et al 529
Volpe M, De Luca N, Indolfi C, Mele AF, Rivera MP, Condorelli M, Trimarco B: Acute hemodynamic effects of atrial natriuretic peptide in essential hypertension 25:S-83
von dem Borne AEGK (abst) 558
Vonesh E *See* Maiorca R et al 518
Waeber B, Aubert J-F, Flückiger J-P, Nussberger J, Vavrek RJ, Stewart JM, Brunner HR: Role of endogenous bradykinin in blood pressure control of conscious rats 26:S-63
Waeber B *See* Brunner HR et al 26:S-80
Waer M, Van Damme B, Leenaerts P, Roels L, Van Der Schueren E, Vandeputte M, Michielsen P: Treatment of murine lupus nephritis with cyclophosphamide or total lymphoid irradiation 678
Walker PD *See* Thakur V et al 494
Walser M, Drew HH, LaFrance ND: Creatinine measurements often yield false estimates of progression in chronic renal failure 412
Walser M, Ward L: Progression of chronic renal failure is related to glucocorticoid production 859
Wandel E (abst) 575, 579
Ward L *See* Walser M 859
Warnock DG: Uremic acidosis (Nephrology Forum) 278
Wauters JP (abst) 575, 579
Weber M (abst) 575, 579
Weening JJ (abst) 556
Weidmann P (abst) 576, 576, 577, 579
Weidmann P *See* Cottier C et al 25:S-72
Westeel PF *See* Idrissi A et al 25:S-138
Westenfelder C *See* Baranowski RL 321
Whiting-O'Keefe Q *See* Petri M et al 832
Whitworth JA *See* Packham DK et al 704
Widmer L (abst) 580
Widmer U (abst) 568, 578, 579
Wieringa B *See* Brunner H et al 507
Wiesel P (abst) 569
Wilkes BM: Increased angiotensin II receptor binding with age in isolated rat glomeruli 241
Wilks ME (abst) 573, 573
Williams JD *See* Topley N et al 404
Winearls CG *See* Sinico RA et al 109
Wiseman MJ *See* Dalton RN et al 117
Womble D *See* Helderman JH et al 376
Worcel M *See* Moura A-M et al 26:S-8
Yabuuchi H *See* Satomura K et al 712
Yamaoka K *See* Satomura K et al 712
Yan X-J *See* Okubo M et al 467
Yanagawa N *See* Suzuki M et al 268
Yañez C (abst) 293
Yang MCM *See* Helwig J-J et al 25:S-45
Yap L (abst) 301
Yokoyama H *See* Saito Y et al 389
Yoshida Y *See* Ichikawa I et al 638
Yoshimura M *See* Saito Y et al 389
Yu SH *See* Lee HS et al 537
Yuzawa Y *See* Fukatsu A et al 611
Zamarrón I (abst) 297
Zaruba K (abst) 573
Záruba K (abst) 579
Zaugg PY (abst) 580
Zbinden M (abst) 577
Zehnder C (abst) 580
Zeidel ML, Seifter JL: Regulation of Na/H exchange in renal microvillus vesicles in chronic hypercapnia 60

Zellweger U (abst) 580
Zereik S *See* Pedrini LA et al 817
Zietse R, Schalekamp MA: Effect of synthetic human atrial natriuretic peptide (102-126) in nephrotic syndrome 717
Zihlmann E (abst) 580
Zimmermann A (abst) 576
Zuccalà A, Santoro A, Ferrari G, Zucchelli P: Pathogenesis of hypertension in hemodialysis patients: A pharmacological study 25:S-190
Zucchelli P (abst) 291
Zucchelli P *See* Zuccalà A et al 25:S-190

Subject Index For Volume 34

(-)15-deoxyspergualin, lupus nephropathy 467
^{123}I-hippurate renography, ACE (abst) 559
[3H] phenamil, amiloride binding sites 26:S-12
17-hydroxycorticosteroids, CRF 858
25-hydroxyvitamin D3
  1-hydroxylase in renal disease patients 712
5'nucleotidase, soluble (abst) 574

ADPKD
  hypertension 683
AIDS
  outcome of patients on maintenance dialysis 248
ATPase
  aldosterone on NEM-sensitive 13
  erythrocyte Ca^{++}-Mg^{++}, 28-kDa-calcium binding protein 262
Acetate
  concentration post-high flux HD, hypotonic (abst) 577
  serum concentration, hypotonic episodes in HD (abst) 568
  slow metabolizers (abst) 296
  untoward effects of anions of dialysis fluids 587
Acid-base
  Na/H exchange in microvillus vesicles, hypercapnia ... 60
  balance in genetic hypertension 25:S-19
  rabbit model of Bartter syndrome (abst) 571
Acidosis
  activity of luminal Na/H exchanger, hypercapnia 60
  hemodialysis, biofiltration (abst) 570
  hypoxic medullary injury 785
  morphological heterogeneity of rabbit CCD 655
  uremic 278
  valproate effect on renal metabolism 645
Acute renal failure
  BN-52021 (abst) 293
  falciparum malaria 866
  glycerol-induced, ACE 321
  post-ischemic, 8-cyclopentyl theophylline (abst) 576
  pyelonephritis (abst) 564
  rheumatoid arthritis, GN (abst) 565
  uranyl nitrate induced, ANP 25:S-79
  vancomycin clearance (abst) 575
Acute tubular necrosis
  quadruple therapy, transplant (abst) 302
Addison's disease, glucocorticoids 25:S-49
Adenosine
  contraction in glomeruli (abst) 289
  ecto-5'-nucleotidase (abst) 571
Adenylate cyclase system, ANP, brain 25:S-98
Adenylate cyclases, PTH 25:S-45
Adrenoceptor a2/b2 ratio, hypertension 25:S-23
Adriamycin nephrosis
  plasma protein concentration, COP 220
Age
  GFR in congestive heart failure 361
  angiotensin II receptors 241
  calcitriol synthesis in SHR 224
  long-term, alternate day feeding in aging rats 620
Akanthocytes in hematuria (abst) 579
Albumin
  plasma concentration in nephrotic rats 220
Alcohol
  pressor mechanism (abst) 298
Aldosterone
  Ang II increases Na, H_2O reabsorption in absence (abst) 574
  NEM-sensitive ATPase in rabbit nephron 13
  antimineralocorticoid compounds 26:S-8
  distal tubule and K excretion 53
  function and control of Na-K-ATPase in nephron 749
  saline infusion, canrenone and Na^+,K^+ pump 25:S-9
Allograft
  fine needle aspiration biopsy 376
Allotypes
  HLA-A, B, DR and Bf in membranous nephropathy (abst) 298
Alpha1 adrenergic receptors, CRF 463
Alport's syndrome
  anti-GBM nephritis post-transplant (abst) 561
  gene localization for X-linked 507
Alsosterone
  K tolerance 397
Aluminum
  concentration, PTG function (abst) 290
  deferoxamine and coated charcoal hemoperfusion removes 803
  gastrointestinal absorption (abst) 290
  removal of DFO-chelated, during HD 98
  risk factors oral, HD patients (abst) 289
  vitamin D (abst) 565
American Society of Nephrology
  John Peters Award 121
Amiloride
  sensitive apical Na^+ channel (abst) 26:S-12
Amino acid
  human and salmon calcitonin, cardiovascular effects 25:S-61
Aminoaciduria, succinylacetone 671
Aminoglycoside, ANP and gentamicin, ARF 25:S-101
Amyloid
  deposits, β_2-m in HD (abst) 300
Amyloidosis
  Muckle-Wells syndrome (abst) 566
  dialysis, visceral involvement (abst) 300
Analgesic abuse (abst) 576
Anemia
  HuEPO treatment in HD (abst) 580
  erythropoetin treatment blocks HD (abst) 577
  microangiopathic hemolytic, ARF (abst) 573
  sickle cell, drugs 500
  working capacity and r-HuEPO 525
Angioplasty, HD access (abst) 573
Angiotensin
  influences on tubuloglomerular feedback mechanism .. 631
  mechanism of antihypertensive effect of K depletion ... 18
  receptor, development of antagonists 26:S-69

Angiotensin II
absence of aldosterone (abst) ... 574
local formation of immune deposits in PCT ... 611
receptor binding and age ... 241
renin is blood borne hormone ... 25:S-33
response in SHR ... 25:S-149
Angiotensin converting enzyme
cardiac changes in uremia ... 25:S-201
determinants of immune complex-mediated GN ... 333
glycerol-induced ARF (abst) ... 321
inhibitor, inducing hyperkalemia ... 25:S-196
local formation of immune deposits in PCT ... 611
peptide effectors studied, peptidase inhibitors ... 26:S-27
Angiotensin converting enzyme inhibitor
^{123}I-hippurate renography (abst) ... 559
unilateral renal artery stenosis (abst) ... 560
Anion
untoward effects of dialysis fluids ... 587
Anionization of antigen, immune complex ... 156
Antagonist
Ang II in development of ... 26:S-69
bradykinin in BP regulation ... 26:S-60
mechanisms of action of vasopressin ... 26:S-38
Anti-GBM nephritis
Alport's syndrome post-transplant (abst) ... 561
proteinases (abst) ... 561
Antibodies
anti-laminin, MGN (abst) ... 556
cytotoxic, post-transplant (abst) ... 294
local formation of immune deposits in PCT ... 611
murine disease (abst) ... 557
transfer of glomerlonephritis by mononuclear cells ... 598
Antibody
polyclonal activation, experimental GN ... 141
Antidiuretic hormone
AVP antagonists ... 26:S-34
vasopressin antagonists in human diseases ... 26:S-48
Antiepileptic drug, valproate ... 645
Antigen
class I HLA in HD (abst) ... 295
glomerular binding and immune complex formation ... 156
relapsing hypertension in pregnancy, HLA DR4 (abst) ... 567
Antiglucocorticoid
probes vascular effect of glucocorticoids ... 26:S-24
Antihypertensive
agents, tubular actions ... 25:S-160
clonidine, beta blockers ... 25:S-181
diuretics ... 25:S-177
drugs in uremic rats ... 25:S-156
enalapril maleate ... 25:S-204
role of drugs in dialysis therapy ... 25:S-198
Antiinflammatory drugs
nonsteroidal, sickle cell anemia ... 500
Antimineralocorticoid
alsosterone compounds ... 26:S-8
Antithymocyte globulin (abst) ... 580
Arachidonic acid
cuprammonium membranes stimulate IL-1 release ... 67
metabolism, CsA nephrotoxicity ... 164
Arginine vasopressin
antagonists, potent and specific ... 26:S-34
use in animal studies ... 26:S-43
Argyria (abst) ... 565
Arteriolosclerosis
diabetic, mesangiolysis and nodular lesions ... 389
Artery stenosis, Captopril, hypertension ... 25:S-138
Arthropathy in HD (abst) ... 301
Atrial natriuretic factor
BP and renal function in hypothyroid rats ... 25:S-104
blunted in liver cirrhosis (abst) ... 556
during mineralocorticoid escape (abst) ... 558
pregnancy, ouabain ... 25:S-89
Atrial natriuretic hormone
BP and volume homeostasis ... 25:S-64
Atrial natriuretic peptide
Ca diet, parathyroidectomy ... 25:S-93
corticosteroid induced stimulation of (abst) ... 576
effect of (102-126) in nephrotic syndrome ... 717
essential hypertension, hemodynamics ... 25:S-83
gentamicin-induced ARF ... 25:S-101
hydraulic pressure in papilla ... 36
hypervolemia in nephrotic humans ... 824
low dose infusion in human ... 25:S-72
mechanism, rat brain ... 25:S-98
mild to moderate CRF (abst) ... 577
plasma levels in dialysis ... 25:S-86
renal clearance of endogenous (abst) ... 563
superficial proximal tubule, loop of Henle (abst) ... 562
uranyl nitrate induced CRF ... 25:S-79

B cell, classical pathway of antibody ... 141
β_2-microglobulin
age, HD and amyloidosis (abst) ... 564
amyloidosis, osterarthropathy (abst) ... 564
factors of plasma concentration during dialysis (abst) ... 300
high flux HD, CAPD (abst) ... 568
kinetics during HD, HF (abst) ... 570
levels in HD (abst) ... 300
serum levels and removal in HD, CAPD (abst) ... 577
BN-52021, ARF (abst) ... 293
Bacteria
wild-type E. coli uroisolates in pyelonephritis ... 760
Bartter syndrome
model in rabbit (abst) ... 571
Berger's disease, HSP (abst) ... 566
Beta blocker, clonidine ... 25:S-181
Bicarbonate
reabsorption, acid-base balance, Na/H exchange ... 60
Biofiltration, acidosis (abst) ... 570
Biopsy
fine needle aspiration utility confirmed ... 376
hepatitis B virus-associated nephropathy in Korea ... 537
pre-eclampsia in pregnancy, post-partum ... 704
Blackwater fever, falciparum malaria ... 866
Blood
abnormal bleeding time in uremia, estrogens ... 852
ionic control of vascular smooth muscle cells ... 25:S-2
Blood flow
ANP and furosemide effects on hydraulic pressure, papilla ... 36
Blood pressure
ANH, volume homeostasis ... 25:S-64
Ang II in SHR, prostaglandin blockade ... 25:S-149
Ca effect on, plasma volume and vascular reactivity ... 25:S-16
alpha adrenergic receptors, CRF ... 463
antihypertensive agents, tubular action ... 25:S-160
catacholamines control of, dialysis ... 25:S-110

childhood hypertension 25:S-115
control, endogenous bradykinin 26:S-63
diabetic hypertension 25:S-133
dietary K 25:S-175
exercise predicts hypertension (abst) 573
genetic hypertension, acid-base balance 25:S-19
hemodynamics of ANP in hypertension 25:S-83
kinins paracrine hormone 26:S-52
mechanism of antihypertensive effect of K depletion ... 18
orthostatic hypotension 25:S-152
prostaglandins in regulation of 25:S-57
regulation, glucocorticoids 25:S-49
renin secretion responsiveness 26:S-80
transplantation, hypertension 25:S-129
treating 2 types of vasoconstriction 25:S-162
tubuloglomerular feedback mechanism in hypertensive rats 631
vascular resistance in ESRD (abst) 573
vasopressin 25:S-52
vasopressin antagonists in human diseases 26:S-48
Body fat sex dependent, hypertension 25:S-122
Bone
(-)15-deoxyspergulain 467
histomorphometry of diabetic, CAPD (abst) 289
osteodystrophy, predictive value of data (abst) 302
primary hyperoxaluria (abst) 301
Bradykinin
BP control in rats 26:S-63
anti-hormones and BP 26:S-60
Brain
adenylate cyclase system, ANP 25:S-98
Brush border
cytoskeleton organization 309
Brush border membrane
hydrolases, lymphocytes (abst) 562
iron, postischemic injury 474
vesicles, succinylacetone 671

C5b-9 membrane attack complex, anti-Fx1A 43
CAPD
β_2m in high flux HD (abst) 568
falciparum malaria 866
histomorphometry of diabetic bone (abst) 289
inulin, lymphatic absorption (abst) 561
oxalate removal during, HD (abst) 578
peritonal membrane function (abst) 561
peritoneal functional parameters, 5 years (abst) 296
phagocyte oxidative metabolism, dialysate 404
sclerosing peritonitis (abst) 579
six year comparison with HD 518
toxic effects of anions of dialysis fluids 587
two-route insulin administration (abst) 296
Calcitonin
human and salmon, cardiovascular 25:S-61
Calcitriol
Ca therapy in hyperparathyroidism 839
production in CRF 368
synthesis in hypertension 224
Calcium
ANP, diet, parathyroidectomy 25:S-93
BP, plasma volume and vascular reactivity 25:S-16
acid-base balance in genetic hypertension 25:S-19
channel blocker, abnormal fatty acids oxidation 773
cortical mitochondrial transport, uremia 327
kidney mitochondria and CsA 234
mobilization in mesangial cells, CsA and vasopressin .. 89
nephrolithiasis, diet 544
salts as alternate phosphate binder (abst) 576
serum level, uremic acidosis 278
toxicity, hypoxic injury 186
transfer during HD 568
transfer during acetate, bicarbonate HD (abst) 577
transport mechanism 262
Calcium carbonate
phosphate binder in HD (abst) 289
Calcium nephrolithiasis
hypcitraturia (abst) 566
Calcium oxalate
monohydrate crystallization kinetics 346
Cancer
renin secreting tumors 25:S-38
Canrenone, Na^+,K^+ pump activity 25:S-9
Captopril
predictability of test in ESRF hypertension 25:S-145
progression of hypertension in HD, pharmacological study 25:S-190
scintigraphy, hypertension 25:S-142
test for renovascular hypertension 25:S-138
Cardiac
changes in uremia, ACE inhibitors 25:S-201
Cardiovascular
diabetic hypertension 25:S-133
dietary K and BP 25:S-175
human and salmon calcitonin 25:S-61
renin secretion responsiveness 26:S-80
vasopressin and BP 25:S-52
Catecholamines
control of BP in dialysis 25:S-110
Catheter
vascular complications in HD (abst) 580
Cation
anionic small proteins (abst) 563
Cell
cytoskeleton organization, brush border 309
s-PAF alters glomerular filtration 778
Children
BP and hypertension 25:S-115
hematuria (abst) 559
lymphatics role in peritoneal dialysis 82
maturation of renal function in infant (abst) 569
post-heart surgery, dopamine (abst) 571
renal functional reserve 808
steroid responsive NS, height (abst) 297
Chinolone antibiotics, HD (abst) 570
Chronic renal disease
heparin effect in nephron 638
Chronic renal failure
ANP in mild to moderate (abst) 577
abnormal fatty acids oxidation, verapamil 773
alpha$_1$ adrenergic receptors 463
anemia and r-HuEPO 525
calcitriol production 368
complement factor D 529
cortical mitochondrial transport of Ca 327
creatinine measurements false indicator of progression 412
enalapril maleate 25:S-204
progression related to glucocorticoid production 858
pyrazinamide and pyrazinoic acid (abst) 563

Chronic renal insufficiency
uremic acidosis ... 278
Cirrhosis
liver, ANF (abst) ... 556
pre-ascitic liver, digitalis (abst) ... 570
proximal Na reabsorption (abst) ... 292
Clearance
endogenous ANP (abst) ... 563
free water, lithium, thiazides (abst) ... 556
measure GFR with non-radioisotopic agents ... 725
vancomycin in ARF (abst) ... 575
Clonidine
beta blocker combination ... 25:S-181
Collagen gels, K transport in PCT, PST ... 268
Collecting duct
inner medullary ... 441
Colloid osmotic pressure
bicarbonate, acetate dialysate (abst) ... 291
plasma protein concentration ... 220
Compensatory renal growth, DNA (abst) ... 292
Complement factor D in RF ... 529
Concentration
magnesium, plasma renin ... 25:S-12
Cortical collecting duct
morphological heterogeneity ... 655
Corticosteroid
ANP induced stimulation (abst) ... 576
CsA, NS (abst) ... 572
Creatinine
false estimates of CRF progression ... 412
serial assessment of GFR in lupus nephropathy ... 831
Crescents
glomerular, EPGN (abst) ... 298
Cryoglobulinemia glomerulonephritis ... 102
Crystallization kinetics ... 346
Cuprammonium membranes, IL-1 release ... 67
Cushing's syndrome, glucocorticoids ... 25:S-49
Cyclophosphamide, murine lupus nephritis ... 678
Cyclosporin A
Ca entry blockers in nephrotoxicity (abst) ... 293
excretion of TxB_2 and 2,3-dinor-TxB_2, nephrotoxicity ... 164
high risk transplantation (abst) ... 295
membrane-mediated functions in mitochondria ... 234
mesangial cell contraction (abst) ... 293
treatment of NS (abst) ... 576
vasopressin-induced Ca^{2+} mobilization ... 89
Cyclosporine
conversion at 3 months post-transplantation (abst) ... 559
low dose, transplantation (abst) ... 301
multiple sclerosis (abst) ... 560
post-transplantation (abst) ... 579
Cytotoxicity
anti-Fx1A produces complement dependent, epithelial cells ... 43

DDAVP
adaptation to chronic hypoosmolality ... 351
DNA synthesis stimulating factor (abst) ... 292
Deferoxamine
Al removal, polysulfone dialyzers ... 98
aluminum removal in dialysis ... 803
mucormycosis in HD (abst) ... 556
Desferrioxamine
visual and auditory toxicity (abst) ... 296
Desmopressin, uremia (abst) ... 295
Diabetes
glycosuric, measurement of PAH ... 117
mesangiolysis ... 389
Diabetes mellitus
hypertension ... 25:S-133
Dialysate
bicarbonate, acetate, HD and COP (abst) ... 291
hormonal, hemodynamic effects of Na ... 25:S-192
how to obtain sterile (abst) ... 573
myocardial function during HD (abst) ... 290
phagocyte oxidative metabolism ... 404
sodium, hemodynamics ... 25:S-187
substitution of phosphate for calcium (abst) ... 580
untoward effects of anions of ... 587
volume measurements, solute transport ... 254
Dialysis
amyloidosis (abst) ... 300
cuprammonium membranes, IL-1 release, arachidonic acid ... 67
different schedules reduce time (abst) ... 291
falciparum malaria ... 866
HIV patient outcome ... 248
ketoanalogs (abst) ... 565
permeability, histamine ... 791
pharmacological study of hypertensive patients ... 25:S-190
plasma levels of ANP ... 25:S-86
quantifying treatment (abst) ... 578
role of antihypertensive drugs ... 25:S-198
six year comparison of CAPD vs. HD ... 518
toxicity of anions in fluids ... 587
withdrawal from ... 124
Dialyzer
down-regulation of neutrophils (abst) ... 575
polysulfone, rapid removal of Al ... 98
Diet
Ca nephrolithiasis ... 544
alternate day feeding effect on aging rats ... 620
Dietetic supplements, HD (abst) ... 297
Digitalis-like naturetic factor (abst) ... 570
Digitonin, GSH in proximal tubules ... 229
Dipropylacetic acid, tubules (abst) ... 292
Diuretic
dietary K and BP ... 25:S-175
dilation of fetal ureter (abst) ... 572
intrauterine (abst) ... 572
Diuretics
as antihypertensive drugs ... 25:S-177
calcium nephrolithiasis ... 544
Dopamine
children post-heart surgery (abst) ... 571
Duplex-Doppler, transplant (abst) ... 293

E. coli uroisolates, pyelonephritis ... 760
Ecto-5′-nucleotidase (abst) ... 571
Edema
ANP and hypervolemia in humans ... 824
GFR in chronic congestive heart failure ... 361
prognostic indicators in NS patients ... 382
Electrolyte
ANP, adenylate cyclase system of brain ... 25:S-98
chronic hypoosmolality ... 351
Enalapril
maleate, renal function ... 25:S-204
renal adaptation to sodium restriction ... 25:S-28

End-dialysis urea rebound 816
End-stage renal disease
  calcitriol and Ca therapy in hyperparathyroidism 839
  doses of r-HuEPO (abst) 558
  estrogens correct abnormal bleeding time in uremia ... 852
  exercise capacity (abst) 291
  hypertension in ADPKD 683
  lymphatics role in peritoneal dialysis for children 82
  platelet function (abst) 291
  removal of DFO-chelated Al during HD 98
End-stage renal failure
  Berger's disease (abst) 566
  Captopril test predictability 25:S-145
  anemia and r-HuEPO 525
  complement factor D 529
  prognostic indicators of nephrotic syndrome 382
  standardized Captopril test 25:S-145
  vascular resistance (abst) 573
Endocytosis of proteins 175
Endotoxin, tumor necrosis factor (abst) 565
Enkephalin
  peptide effectors, peptidase inhibitors 26:S-27
Enzyme
  Na-K-ATPase in nephron 749
  complement factor D in RF 529
  lysosomal, effect of food restriction in GN 765
  morphology of rabbit CCD heterogenous 655
  myeloid lysosomal, autoantibodies (abst) 558
  renin role as blood borne hormone 25:S-33
  renin secreting tumors 25:S-38
Epithelial cells
  anti-Fx1A produces complement-dependent cytotoxicity 43
Erythrocyte
  saline infusion and canrenone, pump activity 25:S-9
Essential arterial hypertension 25:S-14
Essential hypertension
  HLA DR4 in pregnancy 25:S-125
  hemodynamics of ANP 25:S-83
  nicardipine 25:S-184
  ouabain natriuretic factor, ANF, pregnancy 25:S-89
  prostaglandins in BP regulation 25:S-57
  rise of a2/b2 adrenoceptor ratio 25:S-23
  spironolactone 26:S-14
  transmembranous Na^+ transport (abst) 299
  treating 2 types of vasoconstriction 25:S-162
Essential mixed cryoglobulinemia 102
Estrogens in uremia 852
Ethics
  withdrawal from dialysis 124
Excretion
  ANP (102-126) 717
  K, distal tuble contribution in GN 53
  microalbumin rate post-protein (abst) 568
  microalbumin rate, normal protein load (abst) 578
  mineralocorticoid activity, K 697
  rubidium and K 455
  water, AVP antagonists in animal studies 26:S-43
Exercise
  capacity in ESRD (abst) 291
  magnesium and renin concentration 25:S-12
Extracapilar proliferative GN (abst) 298

Falciparum malaria 866
Fanconi syndrome
  succinylacetone, BBMV 671
Fatty acids in muscle, verapamil 773
Fenoldopan in hypertension (abst) 301
Ferritin
  determinants of immune complex-mediated GN 333
Filtration
  s-PAF alters glomerular 778
  ultrafiltration coefficients of glomeruli, biopsies 844
Fimbriae, wild-type E. coli 760
Food antigens, IgAGN (abst) 564
Furosemide
  ANP effects on hydraulic pressure in papilla 36

Gas exchange, hypertension, HD (abst) 290
Gastrointestinal absorption, Al (abst) 290
Gene
  DNA markers in diagnosis of ADPKD (abst) 557
  localization, Alport's syndrome 507
Gentamicin
  ARF, ANP 25:S-101
Glomerular basement membrane
  model of immune complex nephritis 195
  negative charge and immune complex formation 156
  pepsinogens A and C (abst) 561
  transfer of GN through mononuclear cells 598
Glomerular damage, prognosis in NS 382
Glomerular filtration rate
  acute ureteral obstruction 487
  chronic congestive heart failure 361
  creatinine measurements false indicator of CRF progression 412
  glomerular hypertension in progressive renal disease 25:S-119
  glycerol-induced ARF and ACE 321
  hypertension in ADPKD 683
  lupus nephropathy 831
  non-radioisotopic radiocontrast agents 725
  renal functional reserve in children 808
  sex differences, proteinuria 481
  sickle cell anemia, NSAID 500
  tubuloglomerular feedback mechanism, hypertension 631
  ultrafiltration coefficients, human biopsies 844
  uranyl nitrate induced CRF, ANP 25:S-79
  urinary concentrating mechanism, high protein 4
Glomerular size-selective barrier 151
Glomeruli
  ultrafiltration coefficients, biopsies 844
Glomerulonephritis
  15-dsp in lupus treatment 467
  anti-GBM, ethics of treatment (abst) 297
  antigens and IgAGN (abst) 564
  cryoglobulinemia, immune deposits 102
  determinants of immune complex-mediated 333
  distal tubule and K excretion 53
  DPGN prognostic factors 511
  food restriction effect on lysosomal population 765
  hepatitis B, biopsy 537
  histometrical study of 3 glomerulopathies 102
  membranoproliferative, in Spain (abst) 299
  necrotizing, ARF, rheumatoid arthritis (abst) 565
  proteinuria reduced by indomethacin (abst) 562
  transferred by mononuclear cells, chickens 598
  X-linked Alport's syndrome 507
Glomerulopathy
  epimembranous, argyria (abst) 565

Glomerulosclerosis
histometrical study on 3 glomerulopathies..... 102
minimal change disease, mesangial proliferative..... 419
Glomerulus
chronic serum sickness (abst) 559
Glucocorticoid
and antagonists, RU 486 ..... 26:S-18
antagonists as probes of vascular effect of 26:S-24
production, progression of CRF..... 858
regulation of BP..... 25:S-49
Glutathione
distribution, depletion in tubules 229
uptake, protection vs. oxidative injury in cells..... 74
Glycerol-induced ARF, ACE (abst)..... 321
Growth hormone
IGF-I, phosphate transport (abst) 569

H.77, renin as blood borne hormone..... 25:S-33
Hantavirus nephropathy (abst) 567
Heart failure
GFR regulation..... 361
Hematuria
akanthocytes in glomerular (abst) 579
Hematuria, children (abst)..... 559
Hemodiafiltration
paired filtration dialysis (abst) 291
Hemodialysis
acetate slow metabolizers (abst) 296
age, amyloidosis and B2m (abst) 564
aldosterone in K tolerance..... 397
amyloid deposits, β_2-m (abst)..... 300
anemia and r-HuEPO..... 525
arthropathy (abst) 301
β_2-m levels, different membranes (abst) 300
β_2-m kinetics (abst)..... 570
β_2-m kinetics, HF (abst)..... 570
$CaCo_3$ as phosphate binder (abst) 289
Ca transfer during (abst)..... 568
Ca transfer during acetate, bicarbonate (abst)..... 577
catecholamines and control of BP in..... 25:S-110
class I HLA antigens (abst)..... 295
dietetic supplements (abst)..... 297
down-regulation of neutrophils (abst) 575
erythropoetin treatment blocks 577
estrogens correct abnormal bleeding time in uremia... 852
factors of β_2-m plasma concentration (abst) 300
hypertension in, pharmacological study 25:S-190
lymphokines (abst)..... 295
maintenance, chinolone (abst) 570
myocardial function (abst)..... 290
outcome of AIDS, ARC, HIV patients 248
peritoneal parameters, 5 years on CAPD (abst) 296
plasma levels of ANP in chronic..... 25:S-86
platelet function in ESRD (abst) 291
post-, urea rebound 816
proteinaceous material in stones (abst) 564
pulse oxymeter (abst)..... 571
pulse oxymeter studies (abst)..... 578
quantifying treatment for dialysis (abst) 578
rapid removal of DFO-chelated Al 98
risk factors of oral Al (abst)..... 289
role of antihypertensive drugs 25:S-198
schedules to reduce time on (abst)..... 291
sepsis (abst) 296
serum levels and removal of β_2m (abst) 577
six year comparison with CAPD 518
stenosis of access, angioplasty (abst)..... 573
toxic anions in dialysate..... 587
vascular complications (abst)..... 580
Hemodialysis, high flux
hypotonic episodes (abst)..... 568
quantifying treatment (abst)..... 575
removal of oxalate (abst)..... 569
serum acetate concentration post (abst) 577
Hemodynamics
5'-nucleotidase (abst) 574
ANP in essential hypertension..... 25:S-83
Ca and hypoxic injury in medulla 186
CsA and mesangial cell contraction..... 89
GFR in congestive heart failure..... 361
Na dialysate variation 25:S-187
enalapril and sodium restriction..... 25:S-28
heparin effect on nephron..... 638
histometrical study of 3 glomerulopathies..... 102
hormonal effects of Na in HD 25:S-192
hypothyroidism, BP, ANF and renal function ... 25:S-104
mechanism of immune deposit formation 209
nicardipine in essential hypertension..... 25:S-184
sex differences in proteinuria, ultrafiltration 481
sickle cell anemia, drugs 500
Hemolytic-uremic syndrome
prognostic factors (abst)..... 292
Hemoperfusion
deferoxamine, coated charcoal, remove Al..... 803
Henoch-Schonlein syndrome
Berger's disease (abst) 566
Heparin
ACE inhibitor induces hyperkalemia..... 25:S-196
glomerular structure and function of nephron..... 638
Hepatitis
post-transplant (abst) 294
virus-associated nephropathy in Korea 537
Hereditary tyrosinemia, SA..... 671
Heymann's nephritis
anti-Fx1A and complement-dependent cytotoxicity 43
lysosomal population affected by food restriction..... 765
Histamine effects on permeability..... 791
Histocompatability, mononuclear cells 598
Hormone
aldosterone and antimineralocorticoid compounds.. 26:S-8
anti-, bradykinin antagonists in BP regulation 26:S-60
antidiuretic, vasopressin antagonists in human diseases..... 26:S-48
atrial, BP and volume homeostasis 25:S-64
kinins paracrine 26:S-52
molecular mechamism of antisteroid..... 26:S-2
PTH, adenylate cyclases 25:S-45
potent, specific vasopressin antagonists, antidiuretic 26:S-34
renin is blood borne..... 25:S-33
RU486..... 26:S-18
vasopressin and BP 25:S-52
Human diseases, vasopressin antagonists..... 26:S-48
Human immunodeficiency virus
maintenance dialysis, outcome of patients 248
Human recombinant erythropoietin
anemia, maintenance HD (abst)..... 580
Hydroxyl radical, proteinuria 494
Hyperammonemia, valproate..... 645

Hypercapnia
regulation of Na/H exchange 60
Hypercapnic renal insufficiency (abst)..... 580
Hypercatabolism
post-dialysis urea rebound 816
Hyperglycemia
measurement of PAH in glycosuric diabetics 117
Hyperimmunization, transplant (abst)..... 294
Hyperkalemia
aldosterone role in K tolerance 397
induction by ACE inhibitors and heparin 25:S-196
Hypermagnesemia, renin concentration 25:S-9
Hyperparathyroidism
oral calcitriol and Ca therapy..... 839
uremic acidosis..... 278
Hypertension
ADPKD..... 683
aldosterone, antimineralocorticoid compounds..... 26:S-8
Ang II, PG synthesis blockade 25:S-149
angiotensin, tubuloglomerular feedback mechanism ... 631
antihypertensive effect of K depletion..... 18
body fat sex dependent 25:S-122
BP and exercise predicts for (abst) 573
Captopril scintigraphy 25:S-142
calcitriol synthesis decreased in..... 224
children's BP and..... 25:S-115
diabetes mellitus..... 25:S-133
dysregulation, Ca channel blocker (abst)..... 579
enalapril maleate..... 25:S-204
essential arterial, magnesium concentration 25:S-14
essential, Na erythrocyte homostasis (abst) 301
fenoldopan (abst) 301
genetic, acid-base balance 25:S-19
G-induced..... 26:S-24
glomerular size-selective barrier, nephritis 151
glomerular, progressive renal disease 25:S-119
glucocorticoids in BP regulation 25:S-49
ionic control of blood vessels 25:S-2
kinins paracrine hormone..... 26:S-52
nicardipine, hemodynamics 25:S-184
ouabain natriuretic factor, ANF in pregnancy 25:S-89
parathyroidectomy, Ca diet, ANP..... 25:S-93
pharmacological study, dialysis patients 25:S-190
pre-eclampsia in pregnancy, post-partum 704
pregnancy, HLA DR4 ..... 25:S-125
primary reninism 25:S-38
progressive renal disease 25:S-119
prostaglandins in BP regulation..... 25:S-57
pulmonary, during HD (abst)..... 290
relapsing in pregnancy (abst) 567
renin inhibition..... 26:S-73
renovascular, Captopril 25:S-138
saline infusion, canrenone effect on Na^+,K^+ pump..... 25:S-9
scleroderma (abst) 292
serotoniergic S-2 receptor blocker (abst)..... 298
spironolactone in essential..... 26:S-14
standardized Captopril test, ESRF 25:S-145
transplantation 25:S-129
tubular actions of antihypertensive agents 25:S-160
vasoconstriction 25:S-162
Hypertensive
azotemic patients, revascularization (abst) 289
Hypervolemia
ANP in nephrotic humans 824
Hypocalcemia
calcitriol cynthesis decreased..... 224
falciparum malaria 866
Hypocitraturia
acidosis, hypermotility in stone formers (abst) 572
calcium nephrolithiasis (abst)..... 566
Hypokalemia
dietary K and BP 25:S-175
Hypoosmolality
adaptation to chronic 351
Hypotension
Na dialysate variation 25:S-187
orthostatic..... 25:S-152
Hypothyroid
ANF effect on BP of long-term 25:S-104

IgA mesangial nephropathy
main cause of ESRD in France (abst) 566
IgA nephropathy
circulating immune complexes (abst)..... 288
prognostic factors (abst)..... 288
Immune complex
negative charge..... 156
Immune deposit
determinants of GN 333
formation in PCT 611
formation, subepithelial 209
Immunity
mucosal, transplantation (abst) 575
Immunology
acute ureteral obstruction..... 487
fine needle aspiration biopsy for transplantation..... 376
transfer of GN by mononuclear cells..... 598
Immunopathology, polyclonal activation..... 141
Immunosuppressant
(-)15-deoxyspergualin, lupus nephropathy..... 467
antithymocyte globulin (abst)..... 580
Immunosuppression
OKT3 in rejection (abst)..... 579
plasma exchange (abst)..... 575
transplantation, reduced nephrotoxicity (abst) 294
Indicator dilution volume, dialysate 254
Indomethacin
antiproteinuric effect (abst) 297
induced lithium reabsorption (abst)..... 560
reduces proteinuria in GN (abst) 562
Inflammation, s-PAF alters filtration..... 778
Injury
acidosis and hypoxic medullary..... 785
anti-Fx1A, cytotoxicity of epithelial cells 43
antihypertensive drugs 25:S-156
calcium and hypoxic, in renal medulla 186
glomerular hypertension in progressive renal disease..... 25:S-119
hypoxic, calcium in medulla..... 186
iron in postischemic 474
model of immune complex nephritis 195
oxidative, glutathione uptake..... 74
PAN-induced 494
Inner medullary collecting duct..... 441
Insulin
tubular sodium absorption 560
two route administration in CAPD (abst) 296
Interleukin 1
cuprammonium membranes..... 67

dependent stimulation of mesangial cell protein kinase 26
Inulin
lymphatic absorption during CAPD (abst)..... 561
serial assessment of GFR in lupus nephropathy 831
Ion
vascular smooth muscle cells 25:S-2
Iron
post-ischemic renal injury 474
Ischemia
8-cyclopentyl theophylline (abst)..... 576
acidosis and hypoxic injury in medulla 785
calcium and hypoxic injury 186
glutathione uptake protection vs. oxidative injury 74
iron, injury 474

Juxtaglomerular cells
seven renin secreting tumors..... 25:S-38

Kaliuresis
mineralocorticoid activity, K excretion..... 697
Kallikrein-kinin system
bradykinin in BP control 26:S-63
Ketoanalogs effect in dialysis (abst) 565
Kinase
IL-1 and glomerular mesangium 26
Kinin
paracrine hormone..... 26:S-52
Korea, hepatitis B nephropathy..... 537

Landis, Pappenheimer equation..... 220
Lesion
diabetic, mesangiolysis..... 389
histometrical study of 3 glomerulopathies..... 102
minimal change disease, mesangial disorder 419
Leukocyte
acute ureteral obstruction..... 487
Lipid peroxidation, iron..... 474
Lithium, indomethacin (abst)..... 560
Lupus glomerulonephritis
prognostic factors..... 511
Lupus nephropathy
(-)15-deoxyspergualin 467
serial assessment of GFR..... 831
Lymphatics, peritoneal dialysis in child 82
Lymphocyte
brush border hydrolases (abst)..... 562
Lymphoid irradidtion, lupus nephritis..... 678
Lymphokines
synthesis, hemodialysis (abst) 295
Lysosomes
effect of food restriction, GN..... 765

Magnesium
plasma and erythrocyte concentrations, hypertension..... 25:S-14
plasma renin concentration 25:S-12
Malaria, nephropathy in falciparum..... 866
Medical School of Salerno..... 273
Membrane
cuprammonium, IL-1 release and arachidonic acid metabolism 67
cytoskeleton architecture (abst)..... 309
Membrane attack complex, anti-Fx1A 43
Membranoproliferative glomerulonephritis
biopsy study, hepatitis B, Korea..... 537
decreasing incidence in Spain (abst) 299
Membranous glomerulopathy
anti-laminin anutoantibodies, Hg (abst)..... 556
Membranous nephropathy
circulating antibodies vs. Fx1A (abst)..... 288
HLA-A, B DR and Bf allotypes (abst)..... 298
subepithelial immune deposit formation 209
Mesangial cell
CsA and vasopressin-induced Ca^{2+} mobilization in 89
IL-1-dependent stimulation of protein kinase 26
adenosine, contaction in glomeruli (abst) 289
Mesangiolysis in diabetes..... 389
Microvillus vesicles, Na/H exchange 60
Mineralocorticoid
escape, ANF (abst)..... 558
potassium excretion 697
Minimal change disease
distinguished from mesangial disorder..... 419
hydroxyl radical in PAN-induced proteinuria 494
Mitochondria
impairment of CsA..... 234
Mononuclear
cells, transfer of autoimmune glomerulonephritis 598
Morbidity, transplantation (abst)..... 294
Muckle-Wells syndrome (abst) 566
Multiple sclerosis, CsA (abst) 560
Muormycosis in HD (abst)..... 556
Murine disease
antibodies (abst) 557
Murine lupus nephritis
treatment with cyclophosphamide 678

N-ethylmaleimide, aldosterone in nephron 13
Na^+,K^+ pump
canrenone and erythrocyte 25:S-9
Na-K-ATPase
in single nephron segments 749
Na/H exchange, hypercapnia..... 60
Nephrectomy
protein effect, age at (abst)..... 557
Nephritis
model of immune complex..... 195
nephrotoxic serum, glomerular size-selective barrier .. 151
Nephrolithiasis, Ca, diet 544
Nephron
aldosterone, NEM-sensitive ATPase in nephron 13
function and control of Na-K-ATPase..... 749
heparin 638
Nephropathy
hantavirus (abst)..... 567
ischemic, hypercalcemic, and hypoxia 186
Nephrosclerosis, histometrical study..... 102
Nephrosis
PAF in experimental (abst) 288
Nephrotic syndrome
ANP (102-126) effect..... 717
ANP and hypervolemia 824
ANP and hypervolemia in humans 824
anticoagulant proteins (abst) 564
corticosteroids, CsA (abst)..... 572
minimal change disease, mesangial disorder 419
prognostic indicators 382

steroid-responsive, height in children (abst) 297
treatment with CsA (abst) 576
Nephrotoxicity
ANP in gentamicin-induced ARF 25:S-101
Ca entry blocker drugs in CsA (abst) 293
CsA and TxA_2 synthesis 164
CsA and kidney mitochondria 234
bone marrow transplant, CsA (abst) 572
glomerular size-selective barrier, nephritis 151
immunosuppressive efficacy (abst) 294
mechanism of, CsA on mesangial cell contraction (abst) 293
polyclonal activation in nephritis 141
untoward effects of anions of dialysis fluids 587
Nepropathy
diabetic, nodular lesions and mesangiolysis 389
Nonselective uptake of proteins 175
Norepinephrine
alpha$_1$ adrenergic receptors, CRF 463
Nutrition
food restriction effect on lysomes in GN 765
therapy, progression of CRF related to glucocorticoids 858

OKT3
rejection episodes (abst) 579
Orthostatic hypotension 25:S-152
Osmolality
adaptation to chronic hypoosmolality 351
ion control of vascular smooth muscle cells 25:S-2
Osmosis
structure and function of IMCD 441
Osteoarthropathy, β_2m amyloidosis (abst) 564
Osteodystrophy
predictive value of data (abst) 302
Ouabain
ANF in pregnancy 25:S-89
Oxalate
removal during high flux HD (abst) 578
removal during high flux HD, CAPD (abst) 549
Oxygen
acidosis and hypoxic injury 785
Paired filtration dialysis (abst) 291

Papilla
furosemide and ANP effects on hydraulic pressure 36
Para-aminohippuric acid
measurement of, in glycosuric diabetics 117
Parasitic diseases, polyclonal B cell 141
Parathyroid gland function (abst) 290
Parathyroid hormone
abnormal fatty acids oxidation, verapamil 773
adenylate cyclases 25:S-45
Parathyroidectomy
Ca, diet, ANP 25:S-93
Parenchmyal, UPCRAS syndrome (abst) 557
Passive Heymann's nephritis
lysosomal population, food restriction 765
Pathology
John Peters Award, ASN 121
Pepsinogens A and C (abst) 561
Peptidase inhibitor, peptide effector 26:S-27
Peptide
effectors studied with peptidase inhibitors 26:S-27
gene related, human and salmon calcitonin 25:S-61
inhibitor, renin inhibition 26:S-73
low dose ANP in human 25:S-72
Peritoneal
permeability, histamine 791
Peritoneal dialysis
kinetics of, in children; lymphatics 82
Peritoneal membrane
function during CAPD (abst) 561
Peritonitis
dialysate, phagocyte oxidation 404
peritoneal permeability, histamine 791
sclerosing, complication of CAPD (abst) 579
six year comparision of CAPD vs. HD 518
Permeability
structure and function of IMCD 441
Phagocyte oxidation, dialysate 404
Phosphate
binders substitution (abst) 580
calcium salts an alternative binder (abst) 576
Plasma exchange therapy (abst) 575
Platelet activating factor
nephrosis (abst) 288
s-PAF alters glomerular filtration 778
Platelet membrane GP1b, uremia (abst) 295
Polyclonal activation
experimental nephropathies 141
Polycystic kidney disease
DNA markers in diagnosis (abst) 557
hypertension in autosomal dominant 683
Potassium
dietary, BP 25:S-175
distal tubule and K excretion in GN 53
heterogeneity of rabbit CCD 655
mechanism of antihypertensive effect of 18
mineralocorticoid activity 697
rubidium excretion 455
tolerance, aldosterone 397
Pregnancy
HLA DR4 and hypertension 25:1255
dialation of fetal ureter (abst) 572
intrauterine diuretic (abst) 572
ouabain-like natriuretic factor, ANF 25:S-89
pre-eclampsia in biopsied women 704
Primary hyperoxaluria
evolution of bone disease (abst) 301
Progressive renal disease
systemic and glomerular hypertension 25:S-119
Prostaglandin
synthesis blockade in SHR 25:S-149
Protein
CRF progression is related to glucocorticoid production 858
IL-1-dependent stimulation of kinase activity 26
age at nephrectomy (abst) 557
calcium nephrolithiasis, diet 544
cationic and anionic small (abst) 563
customary, kidney function after (abst) 568
high intake, urinary concentrating mechanism 4
hypercatabolism, dialysis, urea rebound 816
natural anticoagulant, adult NS (abst) 564
normal load, kidney function (abst) 578
plasma concentration, colloid osmotic pressure 220
renal functional reserve in children 808
renal uptake of 175
restriction in PHN, lysosomes 765

Proteinase
anti-GBM nephritis (abst) ... 561
Proteinuria
1-hydroxylase activity measured ... 712
falciparum malaria ... 866
hydroxyl radical ... 494
indomethacin, mechanism (abst) ... 297
minimal change disease, mesangial disorder ... 419
pre-eclampsia in pregnancy, post-partum ... 704
prognostic indicators in NS ... 382
sex differences in ultrafiltration ... 481
Proteoglycan
nephritogenicity of, immune deposit formation ... 209
nephritogenicity, model of immune complex nephritis ... 195
Proximal tubule
epithelial cell line from S2 segments (abst) ... 570
superficial, ANP effect (abst) ... 562
Proximal tubules
glutathione ... 229
phosphate transport ... 268
Pulse oxymeter in HD (abst) ... 571, 578
Pump
function and control of Na-K-ATPase in nephron ... 749
transport and calcium ... 262
Puromycin
aminonucleoside-induced proteinuria ... 494
Pyelonephritis
ARF (abst) ... 564
wild type E. coli ... 760
Pyrazinamide, pyrazinamide acid (abst) ... 563

Quinine, falciparum malaria ... 866

RU 486 glucocorticoids, antagonists ... 26:S-18
Radio contrast agents, GFR ... 725
Receptor
Ang II, antagonists ... 26:S-69
molecular mechanism of antisteroid hormones ... 26:S-2
peptide effectors, peptidase inhibitors ... 26:S-27
vasopressin antagonists in animal studies ... 26:S-43
Recombinant human erythropoietin
capacity for work increased ... 525
multiple doses in ESRD (abst) ... 558
Renal artery stenosis
ACE inhibition (abst) ... 560
Renal cortical blood flow
glyceral-induced ARF, ACE ... 321
Renal disease
25-hydroxyvitamin D3-1-hydroxylase ... 712
Renal failure
chronic non-oliguric, Ca channel blockers (abst) ... 579
prognostic factors (abst) ... 288
toxicity of anions of dialysis fluids ... 587
Renal function
long-term, alternate day feeding effect in aging rats ... 620
maturation, infant (abst) ... 569
reserve in children ... 808
Renal insufficiency
anti-GBM GN, ethics (abst) ... 297
vitamin D, 1-hydroxylase activity ... 712
Renin
blood-borne hormone ... 25:S-33
inhibition, inhibitor peptides ... 26:S-73
plasma concentration, magnesium ... 25:S-12
secretion responsiveness ... 26:S-80
seven secreting tumors ... 25:S-38
Renin angiotensin system
acute ureteral obstruction ... 487
age ... 241
angiotensin receptor ... 26:S-69
inhibition, renin secretion responsiveness ... 26:S-80
mechanism of antihypertensive effect of K depletion in SHR ... 18
standardized Captopril test ... 25:S-145
Renovascular hypertension
Captopril ... 25:S-138
Captopril scintigraphy in diagnosis ... 25:S-142
Revascularization, azotemia (abst) ... 289
Reverse osmosis water, dialysate (abst) ... 573
Rubidium and K excretion ... 455

S-2 receptor blockers (abst) ... 298
S2 segments of PT, new cell line (abst) ... 570
Salt
renin secretion responsiveness ... 26:S-80
urinary concentrating mechanism, high protein intake ... 4
Scleroderma (abst) ... 292
Sepsis in HD (abst) ... 296
Serum sickness
caused by BSA, HuIgG, or HuIgM (abst) ... 559
determinants of immune complex-mediated GN ... 333
Sex, body fat, volume, hypertension ... 25:S-122
Sickle cell anemia
nonsteroidal antiinflammatory drugs ... 500
Sodium
absorption, insulin (abst) ... 560
active transport systems (abst) ... 299
amiloride sensitive apical channel ... 26:S-12
dialysate variation, hemodynamics ... 25:S-187
erythrocyte homeostasis in HT (abst) ... 301
function and control of Na-K-ATPase in nephron ... 749
glutathione uptake, oxidative injury in cells ... 74
H exchange in microvillus vesicles ... 60
hormonal, hemodynamic effects in HD ... 25:S-192
potassium load, mineralocorticoid activity ... 697
reabsorption, cirrhosis (abst) ... 292
restriction, enalapril ... 25:S-28
transmembranous transport, essential hypertension (abst) ... 298
Sodium chloride
essential hypertension, acrenoceptor ... 25:S-23
s-PAF
alters glomerular filtration nonimmunologically ... 778
Spironolactone
essential hypertension ... 26:S-14
Steroid
molecular mechanism of hormones ... 26:S-2
withdrawal of, post-transplantation (abst) ... 571
Stone
Ca nephrolithiasis ... 544
crystallization kinetics ... 346
formers, hypocitraturia (abst) ... 572
proteinaceous material, HD (abst) ... 564
Subsegmentation of IMCD ... 441
Succinylacetone, BBMV ... 671
Systemic lupus erythematosus
DPGN prognostic factors ... 511
serial assessment of GFR ... 831

Theophylline, hypercapnic RI (abst) 580
Thiazides
free water, lithium clearance (abst) 556
Thrombotic microangiopathy, HUS (abst) 292
Thromboxane B_2
in CsA nephrotoxicity 164
Toxicity
calcium, to renal medulla 186
deferoxamine and coated charcoal remove Al in dialysis 803
untoward effects of dialysate anions 587
valproate effect on dog metabolism 645
visual and auditory, hemodialysis (abst) 296
Transplant
quadruple therapy, ATN (abst) 302
Transplantation
25-hydroxyvitamin D_3-1-hydroxylase 712
after, CsA (abst) 579
bone marrow, nephrotoxicity of CsA (abst) 572
complication, duplex-Doppler (abst) 293
CsA conversion at 3 months (abst) 559
cytotoxic antibodies post- (abst) 294
fine needle aspiration biopsy in analysis 376
glomerular hypertension in progressive renal disease 25:S-119
hepatitis, graft/patient survival (abst) 294
high risk, CsA (abst) 295
hyperimmunization (abst) 294
hypertension 25:S-129
low dose CsA, ALG and steroids (abst) 301
microangiopathic hemolytic anemia, ARF (abst) 573
mucosal immunity (abst) 575
non-radioisotopic radio contrast agents, GFR 725
withdrawal of steroids (abst) 571
Transport
amiloride sensitive apical Na^+ channel 26:S-12
Ca^{++}-Mg^{++} ATPase functions as Ca^{++} transport 262
cortical mitochondrial, Ca, uremia 327
ethanol effect on membrane Na^+ (abst) 298
function and control of Na-K-ATPase in nephron 749
glutathione uptake, oxidative injury 74
IGF-I, growth hormone, phosphate (abst) 569
ionic control of blood vessels 25:S-2
morphological heterogeneity of rabbit CCD 655
peritoneal solute, dialysate volume measurements 254
phosphate, proximal tubules 268
rubidium and K excretion 455
succinylacetone, BBMV 671
transmembranous Na^+ abnormalities (abst) 299
Triglyceridemia, progression of CRF 858
Triple drug protocol (abst) 294
Tubular necrosis
nephrolopathy in falciparum malaria 866
Tubule
excretion of rubidium and K 455
local formation of immune deposits in PCT 611
Tubuloglomerular feedback
urinary concentrating mechanism, high protein 4
Tubuloglomerular feedback mechanism
ACE inhibition in hypertensive rats 631
Tumor necrosis factor
endotoxin (abst) 565
Tumor, seven renin secreting 25:S-38
Tyrosinemia, succinylacetone, BBMV 671

UPCRAS syndrome (abst) 557
Ultrafiltration
coefficients of glomeruli from human biopsies 844
lymphatics role in peritoneal dialysis for children 82
sex differences in proteinuric levels 481
Uranyl nitrate, CRF and ANP 25:S-79
Urea
rebound, post-hemodialysis 816
Uremia
antihypertensive drugs 25:S-156
calcitriol production in CRF 368
cardiac changes, converting enzyme inhibitors 25:S-201
cortical mitochondrial transport of Ca 327
DDAVP and hemostasis (abst) 295
estrogens 852
orthostatic hypotension 25:S-152
Uremic acidosis 278
Ureteral obstruction
immune cell infiltrate 487
Urinary concentrating mechanism
high protein intake 4
Urine
calcium nephrolithiasis 544
calcium oxalate monohydrate crystallization kinetics 346
creatinine a false measurement of CRF progression 412
enalapril, sodium restriction 25:S-28
formation and uroscopic diagnosis, Historical Archive 273
iron, postischemic injury 474
measurement of PAH in glycosuric diabetics 117
morphological heterogeneity of rabbit CCD 655
Uroisolates, wild-type E. coli 760
Urorenal mortality, analgesics (abst) 576
Uroscopic diagnosis, Historical Archive 273

Valproate effect on dog metabolism 645
Valproic acid, cortical tubules (abst) 292
Vascular
antiglucocorticoids probe effects of glucocorticoids 26:S-24
Vasculilitic syndrome (abst) 558
Vasoconstriction
age and angiotensin II receptors 241
nicardipine 25:S-184
treating 2 types in hypertension 25:S-162
Vasodialator
histamine, peritoneal permeability 791
s-PAF alters filtration 778
Vasopressin
adaptation to chronic hypoosmolality 351
antagonists, development of potent 26:S-34
blood pressure 25:S-52
induced $Ca2^+$ mobilization, CsA 89
mechanisms of action of, antagonists 26:S-38
Venoconstrictor
hypertension in ADPKD 683
Verapamil
abnormal fatty acids oxidation in muscle 773
Villin, cytoskeleton, BBM 309
Vitamin D
Calcitriol in CRF 368
Calcitriol and Ca therapy for hyperparathyroidism 839
co-localization, Ca^{++}-Mg^{++} ATPase 262
increases absorption of Al (abst) 565

Vitamin D_3
1-hydroxylase in renal disease 712
Volume
ANP and hypervolemia in nephrotic humans 824
body fat, sex, hypertension 25:S-122
dialysate measurements, peritoneal solute transport... 254
dietary Ca effect on BP and plasma 25:S-16
end-dialysis urea rebound..... 816
homeostasis, ANH and BP 25:S-64
low dose infusion of ANP 25:S-72
von Willebrand factor, uremia (abst)..... 295

X-linked Alport's syndrome..... 507